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ABSTRACT
PTHrP is produced by primary andcstablishedcavicalkeratinocyteS. However. the (acton
involved in the expression and regulation ofPTHrP in mal ignant cervical cells has not been
charac teri zed The ectocervicar epithcliwn is nonnaJly under the control oftbe S« steroid
hormones. estrogen and progesterone. Hen: I repo rt the effects of known regulators of
PTH rP (EGF, delWnethasoncand I.2S-dihydroxyvitami n OJ) as well as the effects of
poten tial tissue-spec ific regulato rs. 17jl-estradiol and progesterone. on PTHrP ex press ion
and secre tion in thehwnan papill omavirus type 16 (HP V. J6) infected squamous cervical
cancer ce ll line, CaS ki. us ing No rthern analysis and radioimmunoassay.
A dose-d ependent increasein PTHrP mRNA levels \V<ISobserve d in respo nse to EGF in the
a bsence o f r e s . with maximal stim uJation(normaIized. 10 cyc lophi lin) at 20 ng/mL and a J-
fold increase in immunon:active (i) PTHrP at 24 hours . 17p..Esuadio l produced a dose-
de pende nt increase in PTI-lrP mRNA expr-ession wi lh maximal sti mulati on observed. al 10"
M. At this concentration. 17~iolproduceda 2.S-fold increase in iPll-IrP at 24 hours.
Progesterone did not produce a signi ficant dose-depcndent change in PTHrP mRNA
express io n. Nevertheless, the effects of progesterone were examined in time course stud ies
at a concentrationor to" M. A dose-d ependem inhibiti on o r PTHr P mRNA expres sion wa s
observed for both dexame thaso ne and t .25-d ihydro xyvi lam in OJ. wi th maximal e ffects e r
104 M. Both prod uced a 50"/. reduction in iPTHrP relati ve to con trol values at 24 ho urs
in the presenc e of FCS .
Time co urse studies were subsequently performed using those do ses which showed maximal
effects in dose -response experiments. An early increase in PTH rP mRNA expression
(relative to control) was observed in rcspomc to EGF wilh a peak of 4.5-fold at 2 hows.
Both dexame thasoneand 1,2S-dih ydro xyvitamirO} producedonly slightincreases in PTHrP
mRN A e xpression, relative to the time zero (basal ). which we re maximal at 2 and 4 hours.
respectively. However, 24 hours after stimulation, a 50"/0 inhibition of PTH rP mRNA
express ion was observed (relative to control) for bolh horm ones. StimuJation wi th
pro gestero ne resulted in a 2-fold increase in PTHrP mRNA express ion with peak e ffects at
2 hours . Treatment o f the cells with 17jl-estradiol produced a 3.S· fold increase in PT HrP
mRN A ex press ion with peak effec ts at 6 hours.
In HPV·16 established human ectocervical cells (I-IEC-16). it had been previou s ly
demo nstrated thai known regula tors as well as tissue-s pecific rcgu lalotS (progesterone and
17p.esuadiol) modified PTI-lrP production. The pattern of expres sion of PTHr P in Ca Ski
cervical carc inoma cells was simi lar to that observed in HEC- 16 cell s. However , the level o f
iPT HrP secreti on was signi fican tly less in CaSIcicells. Thi s sugge sts a dysregulation of
iii
PTH rP in maIignantcervka1 ceus . The response to me ussue-speci ficsex stero id hormones.
progesterone and 17J}-estr3d iol. suggests an interaction wi th PTHr P and mus a pos sib le
regula tory rok for PTHrP in me eoerrotof ccUularproliferalionand differentiationofceTVicaJ
tissue. These results suggesrlhar. this model of cervical carcinoma ccu ld be used lOassess
me effects of other po tential modulatory factors such as selective estrogen agonists or
progesteroee antagonists .
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CHAPTER t : INTRODUcnON
1.1 G ENERA L BACKGROUND
Parathyro id hormone (PTH) was initially hypothes ized as the: tumour product tha t was
respons ible for hypercalcemia observed in many cancer pat ients . The clinical syndrome.
termed Humoral HypercaJcemia ofMali gnancy(HH M). was found 00 be due to the secretion
by the tumo W'of a cak:cmic factor acting Ollthe sceletce to increase bone resorption and on
the k.idney to decrease urinary calcium excmion. The PTH rP gene was cloned and
sequenced. It has sequence homology with PTHand can therefore interact with the PTH
receptor and mimic the actions of PTH.
I.l HISTORICAL REVIEW
The existence of a parathyroid hormooe-like factor that was responsible for the
hypercalcemia associated with mal ignancy waspostulated near ly sixty years ago by Fuller
Albright (194 1). The theory of "ectopic" PTHproductio n by the tumour was favoured. but
it was not until the 1960's, with the development ofradioinununo assay (RlA) techn iques.
that th is hypothe sis was tested . In 1966, Bernson and Yalowpublished results of the Ilrst
RIA for PTH. in 'ol.bich they found significant d e'lation of PTH levels in the circu lation o f
a number ofhypercakemicpatients sufbing from Iwtg canccr . In the early 1970's. there was
some doubt that PTH itself was the major fac e r involved in produc ing the clinical and
biochemical features of this clinical syndrome. More compreh ensive clinicaland biochemical
investigations followed and indicated tha t the manifestations of HHM were mediated via
PTH receptors in bone and kidney (Mundy GR and Man in TJ, 1982). A sensi tive
cytOChemical bioassay fOf" PTH in kidney cd ls was able todetect PTH-Iike bioacti vity in the
serum cfpatiems in whom immunoreactivePTH was unde tectab le(GoltzmanD elal, 198 1).
Studies in PTH·responsive ROS 1712.8 osteo blastic ce lls showed that the conditioned
medium of three diffet'ent cell lines (inc luding human prosta le carcino ma : PC3, nil Leydig
cell twnour: Rice·500 and rat carcinoma cell line derived from the hypercalcemic varian t of
the Walker tumour : WRC.2 56) couid each stimulate adenylatecyclase in this system (Radan
sa et at, 1983). In this study , peptid e antagoni sts of PTH block ed biological activity, but
preincubation with PTH an tisera did not prevent PTH antagonists from blocking biological
act ivity (Redan SB et al , 1983). This suggested that the active material acting on PTH
rece ptors in ROS 1712.8 cells was immWlOlogically distinc t from PTH . Messenger R..'lA
(mRNA) for PTH could no t be detected in any of the tumours associa ted with HHM
(Simpson ELe l aJ, 1983). Th.is active matetial also had a higher molecular wei ght than PTH
(Benso n Jr. RC et ai, 1974). These observations led investigators to conclude tha t the
substance respons ible for HUM was different from PTH ,
In attempts to identify and isolate the · PTH· like factor", animal models of HHM were
developed and cell lines were established from human tum ours assoc iated with H H M
(Strewl er OJ et al. 1983; G konos PJ et aJ, 1984; Ikeda K et ai, 1988). Thi s led to the
isolation and purification of a prote in from human cancer cell lines wnich revealed the
existence of PTH-re lated peptide (PTHr P). In 1987. the peptide ....-as isolated from a hwnan
hmg cancc:rceUline (Moseley JM ~t aI, 1987), a human renal carcinomaceU line (Strew lnGJ
et 01. 1987) and a breast twnour (Stewart AF et 01. 1981). Subsequen tly. three groups
identified clcres encoding this novel prote in (Suva U r t 01. 198 7; Mangin M et 01. 1988:
Thied e M ~t 01. 19 88).
1.3 PTH rPGENE
1.3.1 Pri mary Sequence:
PTHrP has a mo lecu lar we ight of 17 to 18 kDa (Mose ley JM et 01, 1987). AnUno-t erminal
sequence anal ysis of purifi ed material pointed to significant Ncterminal homo logy with PTH .
Eight of the first thirt een amino acjd residues are identical to those of PTH. but beyond th is
no significant homo logy was obse rved (Mose ley 1M el at. 1987; Stewart AF et 01. 1987;
Sue wlcr GJel al . 1987) {f igun: 1.1).
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Figu re 1.1: Amino acid sequence of PTH(l .34) and PTHrP(I -34 ).
(Adapted from Bilezikian JP. ed, 1994)
The pronounced bcmo lcgybetween PTII and pffirP atlhc N·tenninus led to the discovery
tha t esta blished linear sequential organization of functional domain s in P11-I (Potts Jr. IT .
1971) is also presen t in PTHrP (Kemp BE el oJ. 1987; YatesAJ etal, 1918 ). Thi shomo logy
allowed pmrP to interact with the Pm rece ptor and cause Pm-like effects (Jue ppner H
ttl at, 1991; Abou-Samra AD ttl 01, 1992). Stud ies have shown that the first 34 am ino acids
of both PTH and PTHrP const itute a fully active region of these hormones for activities
relevant to PTH-like effects on mineral metabol ism (Kemp BE et al.; 1987) .
The suue tural organization of the chicken. mouse and rat prnrP genes have been
determined. and all share substantial homology with the human PTH rP (hPTHrP) gene.
Mature PTl{ rPs have been cloned in the human. chicken, rat and mouse . and there is a
remarkab le conserv ation of the primary sequence up to amino acid residue III (Mangin M
et 01, 1989; Yasuda T et at, 1989a; Karaplis AC ttl 01, 1990; Mangin Metal. 1990a; Thiede
MA el ai , 1990b ). Mouse and rat diffe r from hPT HrP by only three ami no acid s. whereas
chicken differs by seventeen amino acids in the corresponding region. Beyond aminoacid
I II there is considerable scqUCfICe divergence . This abfUpt demarcation o f sequence
co nservation implies tha t the res:ion PTHrp(I -III ) is crucial for the bio&ogicaI. function of
PTl{rP. whereas, the res idues C-lermil1al to I II either are not biologically relevant or could
possibly have unique specjes-speciflc functio ns. Allemat ively. these residue s could be
invo lved in stabilization of the protein.
1.3.2 PT H n n., PTHrP:
Chromoso mes I I and 12 are thoughl to have a common ancestral origin because they are of
similar size, centromere index and banding pattern(Comings DE et at. 1972; Mannens M et
01. 1987). The hPTHrP gene is located on chromosome 12 (12p l l .2-p I2.1) whereas the
human PTH gene is loca ted e n chro mosomc I I (I l p I5.4)(Mangin M etal, 1989; Suva U
et ai , 1989). The PTH and PTHrP gcncs appcar 10have arisenfrom an ancientchromosomal
duplication event and represent two members of a small gene family (Philbrick WM el al,
1996). The genes toeseveral other dosely related proteins have been demonstrated on these
chromosomes, consistent with suc h an ancestral relations hip (Mart in TJ et 01, 1997). For
example. msulin-like growth factor II and insulin-like growth factor I ate located on
chromosomes II and l 2,rcspeoctively (MartinTJ et al , 1991). ThePTH and PTHrP genes
have clearly evolv ed separate ly although they have a similar exorv'intronorganization as ~"CII
as a highly homologous sequence at the N-tenn inus of the peptide (Philbrick WM et al.
1996). This may well account for the shared biological targets of PTH and PTHrP. as well
as the interacti on with a common P1Wl'THrP receptor.
The PTH protein is nonnal ly produced by onJy t\I."O[issues. the parathyroid gland and the
central nervous system (CNS), and it func tions primarily to regulate syslcmic cakiwn
homeostasis through its skeletal and renal actions (Bilezikian JP , ed , 1994). In contrast.
PTHrP is produ ced by virtua lly every cell and tissue within the body and has a broad range
of functions, most of which undeT normal circumstances have little to do with cakiwn
homeostasis . The PTH rP Bene has a com plex structure and its prod uct(s) seem to func tion
in an autocriee and/or paracrine (Philbrick WM et at, 19'96) and/or intracrinc (Kaiser SM el
of. 1994 ) fashion . There is mounting cvidcnce to suggest that PTHrP may function
predominantly. ifnot exclus i\'dy, in an autoerineandfor paracrinc fashion (Halloran BP and
Nissenson RA. eds, 1992) and that it has a limited role as an endocri ne hormone . Growt h
factor-like properti es o f PTHr P have been demonstrated in fibroblasts Onsogna KL et of.
1989), ostec btasts (Ce ntre lla M et of . 1989) and embryonal carc inoma cells (Chan SO et of .
1990). PTHrP has less in comm on functional ly with PTH than with epidermal gro wth
factor (EGF), transforming growth factor bela (TGF-~). insulin-like gro wth factor 1 (IGF-I) ,
or any o f a numberofdevclopmcnla.lfactors. A more appropriate name might be TGF -y or
a name that reflects its dcve lopmenla.land physiological roles (WysolmerskiJJ and Stew art
AF. I99 8).
pm and PTHrP ate equip>tent in most of their acute effects and in rccqxorbinding. de spite
the divergence:of the primary sequence in the 14-34 amino acid domain (Orloff JJ et of.
I989). PTH(14·34) and PTI-lrP(14-38). fragrncntswi th entirel y divergent sequences , both
compete for PTH rece ptor binding. albe it weakly (Abo u-Samra AD el of, 1989). Althoug h
PTH and PTHrP arc dissimilar in their primary struc tures in the 14-34 region, they arc
highly similar in conformationalorthree-dimcnsiona1terms (F'hilbrick WM et at, 1996). Thi s
is an unusual and important example of shared function due: to similarity of
secondary/tertiary structure , in the faceof a remote telation ofprim asy amino acid sequence.
1.J.J Human PTH rP G~D~:
The hPTHtP gene is . complex transcriptional unit spannin g appro ximately IS kb (Suva U
et ol, 1989; Yasuda T el al , 1989b). It can produce multi ple PTH rP mRNA spec ies. and
these, in tum. encode more than one product (Suva U et al , 1919; Yasuda T et al. I989 b;
Kaiser SM and Goltzm an D, 1993). Although there is no uniform nomenc lature for the
exomc organization o f the PTHr P gene. it has been general ly accepted that the gene is
composed of nine exons (Martin TJ el o/, 1991; Moseley 1M and Gillespie MT. 1995)
(Figure 1.2).
Figure 1.2: O rganiza tion of the human PTHrP gene . The coding reg ions
(closed boxes). untranslared regio ns (open boxe s), promoters (arrows) and splicing
eve nts (be low the ma p) are shown . (Adapted from Mani n TJ et al , 1997)
The gene is transcribed by func tional ly distinct promoters. and mRNA tran sc ripts can be
e nernauvety spl iced both at the S' and3' mds(Mangin M et al; 1989; YasudaT el al,1 989b;
Vasa vada RC el al , 199 3). Throughaltemative sp licing , the multi-exoruc PTHr P gene gives
rise 10 three initial uanslation products: PTHrP( I -1 39), PTHrP(I·141) and PTHrP(I-173)
(Bilezikian JP, ed , 1994 ). "These undergo exte nsive posttranslational processing giv ing rise
to a family of mature secretory fonns of the pep tide, each with its own physio logical
function s (Orlo ff JJ et 0lI. 1994 : Wysolrnerski JJ and Stewart AF. 1998 ). For example ,
PTHr p( I-36) initiates mul tipl e everas including vasorC'laxation,.bon e reso rpt ion and cenular
pro liferation (Wyso lmcnki J1 and Stewart AF. 1998 ). PTHrP( 107·13 9) inh ibits bone
resorpti on (Fento n AJ e t oJ. 199 1). The physiolog ical functions of 1hc:mature sec retory
fonns of PTHrP are the subject of ongoing inves tig ations. The PTH rP gene is far more
co mplex than the PTH ge ne, whic h hasonly three exons . However , they po sse ss simi lar
exoruc regions encodingthe peeprc- sequence (Mose ley JM and Gillespie MT , I99S) .
PTHr P exists as a single copy gene (Yasuda T et ai, 1989b).
Exons I thro ugh IV ate noncoding exons, and can be fused in various way s as a result o f
promoter usage and/or alternate splicing patterns to generate S' untranslated regions (UTR s)
that differ among PTIlrP rnRNA species (S uva U et o f, 1987; Mangin M et ai, 1990 b).
Canonical TATA promoters have been found S' to exons I and IV, while S' to exon m is a
GC·rich promoter region. These promoters have been identi fied by prime r extension. 5 1
protecti on and tran sient transfection analy ses (Thiede MA et ai, 1988 ; Man gin M et 01.
1989; Suva U et ai, 1989; Campos RV et aI, 1992; Vasavada RC et al, 1993) . The three
spatia lly distinct promoten ate respons ible for transcription ofthc human gene , and appear
to be different ially regulated (Man gin M et 01, 1990b; Vasavada RC et 01, 199 3; Southb y J
etal, I99S ). The existence and usc o f alterna tive promoters suggests that tiss ue-speci fic
expre ss ion o f 1he gene may occur as a function of 1hc usc of differing promoter regions and
points to co mplex gene regulation (Manin TJ et ai, 199 1). Exons V and VI are invari ant in
mature PTHrP mRNA species described to da te. Exon V encodes most of the Ihiny nine
amino acid prepro- orsi gnal sequencc ofP THrP . Exon VI encodes the majori ty o f lhe coding
region for the mature protein, up to residue 139, where asplice donor is loca ted ; this excnic
organization is similar to that ofthc PTH gene (Martin TJ el ai, 1991). A key '1t.inge M
sequence occurs at the end of the cod ing region in exon VI. This four basepa ir sequence ,
GTAA. plays the dual role of a splice donor site (GT consensus ) or sto p codon (T AA)
(Bileziki an JP. ed , 1994 ). Read- through of exon VI and VlI results in the introd uction of a
terminal signal , th us producing a protein produ ct 139 ami no acids in length . Splicing of exon
VI 10 own VIII or exce VI to CXOI1 IX results in C-temUnal extensions o f PTHrP and
prod uces malUre iso formsof 173 and 141 amino acids, respectively (Yasuda T et al. 1989b ;
Mangin M er al, 199Ob ). Th us. allemative 3' splicing prod uce s prote ins with variable
carboxy l termini . which are of unknown biological significance at present . The 3'.
untranslared sequences of some genes ma y play a role in developm ent or in tissue-specific
gene ex press ion whereas PTHrP has been determined to be nec essary for normal
deve lopmen t (Cramer SO et 01. 1996), investigators have not found any tissue- specific gene
expressio n to dat e.
1.3.4 Early Rnpoase Geoe:
The pro mote r region o f the PTHrP gerw: contains nuc leotide seq uence mo tifs similar to
members of the ear ly response gene fami ly. lmmedlare-early response genes include a
number of transcrip t ion facto rs such as c-myc and c-fos or cytokmes such as M-CSF and JE
(Jones TR. 1987 ; Wilson T et aI. 1988; Vakaklpoulou E ~I ai , 199 1) with half-l ives of
approxima tely 30 min utes . Thesegenes, like P11irP (Orlofsky A and Stanl ey ER, 1987).
are induced when resting cells are treated wi th rrutogens, whi ch suggest tha i they may be
involved in a casc ade that initiates progre ssion through the cell cycl e. Th us, their targe ts are
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likely to be involved in initiating or promo ting gro wth (Felig Pet 01. eds, 1995) . Hence,one
would expect an increase in the acti".;ty of thesc genes to be associated with oncogenesis.
Compara tive analysis and transie nt transfection o( promoter constructs have revealed that
many of these genes co ntain serum response elements (SREs) in the ir 5' flankin g sequences.
and that the!l: SREs are essential (or induction in response to growth (actors (C hristy B and
Nathans 0 , 1989).
The immed iate-early genes also co ntain multi ple copies of an AUUUA motif in the ir 3'·
untransl ated sequences . Messenger RNAs invol ved in cellularprol ifererion or di fferentiation
commonl y have motifs rich in adenine and uracil (AU) in their 3'· untrans lated regions
(Cleme ns MJ. 1981). which contribute to instability and rapid tumover ofthe mRN A (Shaw
G and Kamen R. 1986 ; Kaiser SM and Golttman D. 1993). Each exon spec ifying the 3'·
unuanslated sequence of PTHrP mRNA contains multiple copies o f this instabili ty motif
(exons Vn and IX each co ntain 4 copies of the AUUUA moti f. while exon VIII contains 2
copies ) [Yasu da T et al; 1989b; Mangin M et 01. 1990b). These motifs are highly conse rved
in the unrrans latedregi ons of all PTH rP mRNA s from chicken to man. but are absen rm PTH
(Heinrich G et al. 1984 ; Mangin M et al , 1989; Yasuda T et oJ. 1989b ; Karap lis AC et oJ.
1990; Mangin M et al,l990b).
These findings suggest that rapid mRN A turnover is critical for proper regulation of PTHrP
"
mRN A expression and biological function (Halloran BP and Nissenson RA.eds. 1992). II
appears that the express ion of PTHrP mRN A is Wldera tight contro l through a combinatioo
of transcri ptional and posttranscrip tionaJ mechanisms. Thi s pattern ofcontrol presumably
accounts for the low level of PTHrP mRNA thai is prese nt in most, if not all, cells th at
express the gene constitutively, as we ll as the rapid and transien t PTHrP mRNA responses
that have been observed in a nwnbe!' of tissues fcljowing stimul ation (1bi~ MA d of.
199Oa; Kremer R rt al. 1991). These kinetic features would appear 00be highly relevant to
the proposed autocrine , paracrine and intJ'aCrinc ecuces of PTHrP observed in cells tha i
secrete the peptide via the con stitutive pathway; how these feature s might affect control o f
PTH rP gene express ion in a regulated secretory cell is unclear (Ha lloran BP and Nissenson
RA. eds, 1992). PTItrP mRN A has been found oohave a short half-life in thc range of thin y
minutes to three hows (phi lbrick WM et al, 19(6). supporti ng the notion that the presence
o f the AUUUA sequence produc es mRNA instability. In transi ent transfcc tione xpcriments
in which copies of th.is sequence were deleted from the 3'-untran slated sequence of c-fcs or
c-mye, mRNA transc ripts were stabilized (Jones TR et al, 1987; Wilson T er 01. 19&8 ).
Inhibition of protein synthes is as a resul t of cyclohcxamidc treatme nt produces mllNA
stability and suggests thai the AUUUA motif may direct the degradation of PTHrP mRNA.
In addition, cycloheximide transcripti onally induces PTHr P expression in a variety of cell
lines (AllinsonET and Drucker OJ. 1992; Kiriyama T et ai, 199] ). This phenomenonisaJso
observed with other me mbers of the early response gene fam ily (Greenberg ME et of. 1986).
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There fore, theexprnsionofthe PTHrP gene hasthe kinetic s ofa so-c.aled immediate-carly
gene. The regulation of P11{rP mRNA express ion is reminiscent of the control of a num ber
of cytokine mRNAs and is cons istent with that o f a predomin antly const itutivel y secreted
produc t with powerful regulatory effects . Therefore , PTH rP has features which suggests its
involvement in cell ular gro wth and difTet't'ntiation (Kaiser SM til 01, 1992; Kaiser SM et 01.
1994).
Another feature of PTI-lrP whic h is also seen in other membe rs of the earl y respo nse gene
family is the prese nce of a j -mer sequence, TlTTGTA. or its inve rted sequence.
TACAAAA. in the ) '· untrans lated region . The PTHrP gene conta ins this sequence within
exo n IX, the inverted repea t is foW\d in exon VIIand the inverted repeat with one nuc leotide:
mismalCh (TAQAAAA) with in exon VIII (Thi ede MA elol. 199Ob). A number of
transc ription factors inclu din g c-jun • jun. junO, c-fcs . fosB and the cytc kines JE , IL-2 and
M-CSF have this sequence in their j'cuntranslared region s (Mo seley JM and Gill espie MT.
199 5). The sequence is not involved in polyadenylanon, splicing or destabi lization o f
transc ripts. However , as all immediate -ear ly response genes arc induced by serum . it has
been postulated that thi s sequence alon g with the SRE may be essential for traffic king o f
mRNA for prote in syn thesis (Freter RR til ai, 1992).
IJ
1.3.5 POlt· Yr.. s1. lio• • 1 PreccSliDC:
As soon as the threecDNA·pred"=1edPTHrP amino acidsequcnccswereasaertained..i1 was
d ear tha t PTHrP co uld underg oex1ensive posnranslatKmal PfO':c:ssingand migh t serve as a
prohormone or po lyprotein from which a fami ly of peptide hormones could be de rived .
That is, the cDN A sequence s encode a typ ical prep ro- or signal sequence wi th a
hydropho bic core of I()..IS amino acids flanked u pstream and dcwn stream by charged amino
acids. The pre- sequence is generally Ihought to be removed as Ihe nascent peptide enters
the cisternae of the endopl asmic reticulum and is unlikel y to persist in the:cell (Liu B et af.
1995). Intraeellularcoov~ionof pro-PllirP 10 the ma ture peptide is req uired, and removal
o f the: pro- sequence most likely occurs in me Golgi apparatus (Liu B et al , 1995).
Moreover, the primary seque nce of the mature PTHrP peptide contain s mult ip le clusters of
basic amin o acids in the co nserved region (tha t is . up to ami no acid I I I) arranged in pairs.
tripl ets and quadru p les (Philbrick WM et al, 1996 ). These cl usters are potent ial s ites for me
act ion o f processing enzym es . several of which exhibit the features of cc nvertase (or dibasic
processing endo pro teasesj target sites (Gillespie MT and Mart in n . 1994) . Althou gh it has
not beenproven. thi s raises the possibility thai u ssce-speetnc posnranslational processing
events will be important in characterizing the ciIQJ)ating forms of PTHrP as well as
understandin g the biologica l actions c f tbese pcptidc:s.
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I ....AUTOC RINE AA"D PARACRl1II'l: FUNCTIONS O F P'TIIrr
Autoc:rine secretion is defined as a mechanism by \o\ruch a ceu secretes a hormone-lik e
substance for which the ceu itse lf has functio nal external receptors. Paracrine regulation
involves the sec retio n of factors (such as bormones, growth factors. and cytokines) by one
cell. which diffuse through the extracellular space to their ultimate targe t ce lls. PTHrP has
diverse biologic activities in many nonna! tissue s which are mediated by the PTHIPTHrP
receptor . At times. PTHr P is secretedvia the classical secretory pathway and interacts with
cell surface receptors in an autocrinclpwacrine fashio n \o\ruch suggests that PTHrP has
multiple effects . Targeted expression of PTHrP delay s endochondral bone formation
(Schipani E et aI . 199 1) . More reeeeuy , PTH rP has been found to directl y signal to the
PTHlPTH rP receptor on proliferating cbondrocytes to slow their differentiation (Chung UI
et al. 1998). It is essential in numerous develo pmental events inchlding inductio n o f
differentiation to ward parietal endodenn in F9 embryo nal carcinoma ce lls (Verhcijen w-f et
al , 1999 ). epidermal differenti ation in ad ult mice (Fo ley J et al . 199 8) and mammary gland
development (Dunbar ME et 01. 1999). It is involved in apcpmsis in vari ous systems such
as the:insul in-producing be ta ce lls ofthe: pancreanc is let and the vascular smoo th musc le cells
of the aneria! wal l (Vasavada RC et al, 199 8). It is undi sputable thaI PTHrP has man y
importanl autoc:rine and parac rine functions . Scien tific research is find ing and co ntinues to
find new roles for PTH rP.
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1.5 PTf lrP RECEPT ORS Al'\Il) SIGNAL TRAN SDUcnON PATIIWAVS
As described in 1.3.5. there is abundant e:vidmcc that PTHr P is a polyprotein W t is
cleaved/proce ssed into multiple produc ts. Since PnlrP is posnranslationaJly processed to
a range o f mature secre cry fonns with distinct intrinsic bioactiviti es. it is clear that multiple
receptors for PTHrP must exist. The multiple products can be divided into three categories:
I. An amino-tenninal PTHrP secretory fonn, PTHrP(1-36) , which interacts with the
classical PTHlPTHrP receptor (ty pe 1 cell surface receptor ) (Or lo ff JJ et ai, 1994). and
possi bly with an as yet struc tural ly undefined amino-termina1PTHr P recep tor (Orloff JJ d
al , 1995). PrnrP is thought to exC11 its bio logical effects by bindin g to and activating [he
ty pe I surfac e reccptor(Or loff JJ et a l, I994; Philbrick WMet al.I996). This mediates at
least some of the local paracrine!autocrineactionsofPrn rP (Ng uyen MT and KaraplisA C.
1998) including vascular smooth muscle cell relaxationand cellular proliferation (Orloff JJ et
al, 199 5). The most well established effects of PTHrP are medi ated via this receptor
including promotion of urinary cycl ic AMP and phosphate excretion and a reduction in
calciwn e xcretion (Manin TJet al. 1991). There is also evidence that PTHtP employs its
ow-n uniq ue receptors in addition to the class ical P1lIIPTIIrP G-protein co upled receptor .
2. Mid-region PTIIrP appears 10 have its own receptor which medi ates acti vities such as
placental calcium transport (Rodda CP et al. 1988)and inhibition of the gro\\ th of a breast
carcinoma cell line (Luparello C et al , 1995). This putative midregion receptor appears to
signal exclus iveiyviathe calciwn messengersystem (ph ilbrickWM . 1998). 3. The carboxyl-
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lenni nal PTH rP peptide. P'THrP(I 0 7-139 ). appe ars to act via a separa te recep tor and
mediates o ther actions such as inhibition o f osteoc lastic bone resorpti on (Fenton AJ et ai.
1991). l ess is known regarding the recepto rs for the mid-region and carboxyl-terminal
hPTHrP peptides . These receptors are the subjec t of ongoing invest igations.
1.6 MECII ANISMS OF PTlirP SEC RETION
PTHrP is unusual in that it has feature s of both a neuroendocrine peptide and a grcwth factor
or eytckine (Martin TJ et al, 1997). Peptide hormones are small protein s. Their mRN A
encodes initial trans lation producu wbic h are larger than the secre tory form of the peptide .
That is. mRN A is trans lated into pro tein prec ursors. which are then processed by a series
of proteol yt ic cleavages to yield the final secreto ry prod uct. Growth factors are
polypept ides which regulate cell proliferat ion through binding to spec ific receptors. They
constitute a large groupofhonnones with prominent actionsoncell proli feration.as oppo sed
to the e ffects on differentiation and secret ion that are typica l of man y other peptide and
protein horm ones .
PTH rP is like a IlelJl"Oendocri peptide in tha t it undergoes extensi ve posura nslat iona l
processing in a fashion analogous to proop iomel anecortin or so matos ta tin and it is the
product of a broad variety of neuroendoc rine cell types. including pancre as. pituitary cells
and the centra l nervous system (Orloff )} et al. 1994). PTHrP enter s the class ical secretory
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pathwa y, beginning with signal peptide -mediated entry into the endoplasmic reticuJum(ER) .
it then rransversestheGclgistaeks and the trans-Go lginetworK. Subseq uenUy, it eruers the
transpo rt vesicles o f the consti tutive secretory pathway or the sec retory granules of the
regulated secretory pathway (\Wich varies in different tissues), and finally it tmde:rgoes
posttranslational glycosylation and cleava ge by prohormone con verta ses (Wysolmerski JJ
and Stewart AF, 1998). The PTHrP secret ory protein is synthes ized as precursors
conlaining an amino- lemtinaI signal sequence which mediates interac tions between the
growing peptide during rranslation and the membrane of the ER In these cells, PTHrP is
packaged into secretory granules (Ph.ilbrick WM el al, 1996) .
On the othe r hand, PTI-lrP is also produced by a broad range of eonstitutively seeming cell
types including keratinocytes, chondrocytes and vascular smooth musc le cells (philbrick
WM et al . 1996). In these cells. which do not contain neuroendocrine sec retory machinery.
PTHrP is secreted in a constitutive fash ion (Mart in T J el aI. 1997). Thi s duality of
secretory mechanisms has not been documented for other peptides in d ifferent cell type s
(Philbrick WM ~I 0/ , 1996).
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1.6.1 PTHrP ••d Nuclear Localiullio. Sip.b (N LS) :
Regardless of size, some proteins functioning wi thin the nucleus possess a nudear
locaJization signal (NLS) which is required for recogni tionby and active trans loca tion through
the nucl ear pore com plex (DeRobcrtis EM et al, 1971; Henderson JE et 01, 199 5). Nuclear
locali zatio n signa ls: (I) an: typicall y short sequences, usua lly not longer than 8-10 amino
adds; (2 ) co ntai n a high proportion of posit ively charged am ino acids (lysine and arginine):
(3) an: no t located at specific sites within the protein: (4) are not remo ved following
local izati on; and (5) can occur man: than once in a gi"a1 protein (Gan::ia.Bustos J et 01,
199 1).
II appears that some e ffec ts of PTIlrP may be:mediated thro ugh inlJ'aerine meehanisms via
nuclear or nucleolar targeting (Kaiser SM et 01, 1992: Kaiser SM et 01, 1994 ; Henderson IE
el al, 1995). PTHrP con tains a biparti te nucl ear local ization signal in the:midregio n (am ino
acids 87.107) of the protein (Kaiser SM et at, 1992: Meero vitc h K et al, 199 7). This fmding
was unexpected because: native: PTHrP includes a peepro- (leader) sequence that w'ou ld
normal ly tar get the nascent protein to the endo plasmic rc:tieulum for sc:cret.ion(Nguye n MT
and Kara plis AC. 1998).
The PTHrP sequence contains three c lusters of basjc residues in the (B7· 106) rcgion that arc:
similar in sequence and configuratio n to lite single and bipartite nuclear or nucleo lar
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localization scqucnces in viral transcription factor'$. such as basic fibroblast gtO'olI1h facto r
(hFGF) and fibrob last growth facto r-S (FGF.J) (Kai ser SM et al, 1992 ; Kaiser SM et aI.
1994). PTH rP can be identified by immunocytochemi suy in the nucleus, and has been
dem onstrated in the nucleolus of immo nal ized human cctoce rvica1cells (H EC-1 6) (Rahim tula
M and Kaiser SM. submi tted) and in COS-7 ce lls transfccted with PTHrP (Henderson IE
et 01. 1995) . Deletion of the mul ribas ic(B7-106) rqion pre t..cnts thi s nuckarlocalization.and
dele tion o f the PTI-lrP signal peptide. whi ch would divert PTH rP awa y from the secretory
pathway, enhances nuclear locali zati on (Henderso n IE et ot, 1995).
The quest ion arise s here as to how PTH rP can. under some circums tances, enter the
secre tory pathwa y and at the same time . avoidenuy into the ERto remain in the c)toplasm
and enter the nuckus. This phenomenon has beendescribed for a variety of pcpt ide growth
factors including bFG F (Hi ll OJ el aI. 1992) and FGF- J (Kie fer P el aI. 1994 ). These
peprides are knO\VII to modul ate cellular function via a dual mode of action : firstly. b y
extracellular activation of clas sical signal transduction pathwa ys. and seco ndly. by nuclear
actions tha t critical ly re ly on an endocytcsis-dependentpathway _ One proposed mechanism
whereby PTHrP might find its way to the nucleus is through secretion via the classical
secr etory pathway . followed by recc ptor-mediated endocytosis/ internalization of the
receptor-ligand complex and release of the PTHrP ligan d wilhi n the ce ll. Once entry into lhe
ce ll has been gained. nuc lear local ization could be mediated by nuc lear or nucleolar targeting
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signals (Wysolmerski 1J and Stewart AF. 199 8).
A second proposed mechanism for PTHrP nuclear localiza tion suggests that secreted
prote ins can be diverted from the default secretory pathway and targeted 10 the nucleus by
altema tive initiationo r trans lation at non-AUGcodons. in particuJar.CUG (Nguyen MT and
Karap lis AC. 199 8). This mechanism to bypassthe sec retory pathway has been described
for FGF·3. Here. a CUG· initiated species was shown to have dual fales, either secretion or
nuclear targeting (}(jefer P et 01. 1994 ).
Another potential mechanism has been suggested whe reby. under some circumstances
secreted proteins might W\dergo recruitment via interactions with sequestering proteins or
chaperones. and subsequent trans location to the cytoplasmi c departme nt (Nguyen MT and
Karaplis AC. 199 8). II is W1Clear whdher this may occ ur by reversal of the trans locat ion
machinery or by a distinct tran sport system. Reversal of the early steps of protein
commitment to secretion makes this pathway a plausibl e mechanistic alternative for the
trans locatio nor PTIirP frcm the ER lumen to the cytoplas m (N guyen MT and Karaplis AC .
1998).
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1.7 PTI l rP EXPRESSION
Although initially discovered in mali gnancies.,the prod uction of PTH rP mnonnal tissues was
first demonstra ted in 1986 by Merendino 11 et al where a "PTH -like" activity was identified
in cultures of nonn al human epidermal kerat inocytes. Following the cloning of PT Hr P
c DNAs, an intriguing and extensive list of tissue s ,...hi ch produce this moIecuJe has been
asse mbled. PTHrPis prod uced by many normal and mal ignan t tissue s. particularly those
of epithelial origin (Grone A et ai, 1996). Many histological types of cancer celts produce
PTI-lrP (Danks AJ et al , 1989; Drucker OJ el al, 1989. Asa SL et al, 1990; Kaiser SM and
Goltzm an 0 , 1993). PTHrP protein andlor its mRNA have been dem onstrated in the nonnal
adu lt brain, uterus. cervix , placen ta. amnio n, lym phocytes, lactating breast, pancreatic islets ,
kidney , osteob lasts . chondrocytes.,adrenalcor1exand medulla. urinary bladder and vascular
smoo th muscle, as well as in numerous fetal tissues (Orlo ff 1J and Ste~'3TI AF. 1995;
Philbrick WM et aI. 1996). Essential ly, PTHrP is produced by vinually every ceUand ti ssue
within the hwnan body at some point in development (Wysolmerski 11 and Stewart AF .
1998) .
The identificaton of PTH rP in a wide variety of norma..l cell ty pes . the express ionof PTH rP
in d iverse tissues during development and the presence of PTH rP receptors in many tissues
suggest that PTHrP has a ro le in nonn al growth. devel opm ent and differentiation in these
cells and tissues (C ramer SD et at, 1996)
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1.8 REGUlATION OF TIlE Pnlrf> GEl'\I""E
The PTH and PTI-lrP genes appear to be regulated quite differently. Physio logical contro l
of the PTlI gene is limitedto caiciwn and 1.25-dihydroxyvitaminD )oand the ec neot a ppears
to be exclusively at the level of gene transcription (Okazaki T et ai , 1992) . In contrast, a
wide variety of agents has been reported to influcnce steady-sta te PTH rP mRN A levels
and/or gene transc riptio n. The gene appears to be subject. to tight co ntro l through a
combination of transcrip tiona l and posnran slational ma::hanisms(Holt EH el ai. 1994 ).
Some elements involved in this regulation inc lude the three alternate promoters. a nwn ber of
positive and negative regulatoryelemmts. as well as.. posnranscriplionairegulation(Phi lbrick
WM el a/,I 996).
Two characteristic pa ttern s of physiologic or pharmacologic stimuli have been reported. one
consisting of a prolonged or plateau response , lasting many hours to days (Chan SD et 0/.
1990 : Thiede MA et 0/. 199(3) and the second characterized by rapid induction-deinduc tion
kineticsoccurringover one to~eral hour.> (lkeda KelaJ, 1990 : Kremer R el a/. 199 1). The
kineti cs of the seco nd type of response are reminiscent of those o f a nwnber of
protooocoge ne ard cytokine mRNA s including. forexample, c-myc.c -fosand M -e SF. A U-
rich eleme nts (MEs) o r instabi lity moti fs tha t were initially identified in these mRNA s an:
also present in PTI-lrP mRN As, which similar ly have been found to be unsta ble (Ho lt EH
et 0/, 1994) as discussed in 1.3 .4.
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Estrogen has been reported to dK:i:t both patterns of PTHrP mRNA res ponse . The
administra tion of 17P-cstradiol to ovariectomized or intact rats in vivo leads to a trans ient
PTHrP mRNA response in the uterus, with a peak occurring 2 hours aft er administration
(Thiede MA et al , 199 1). 1 7~·Estradiol admini strati on 10 human papiljoma virus type 16
(HPV416) immortalized hwnan ectocervical cells also produces a peak PTH rP mRNA
response at 2 hours. with a return to basallevels by 72 hours (Rahimtula M and Kaiser SM.
submitted). In contrast, when 17Jksttadi ol was admini stered to rat myomeaial cells in
primary c ulture , a plateau type of response was observ ed, with peak PTl-lrP mRN A levels
at 24 hours . and main tenance of theselevels for up to 5 days ( Thd de MA et al . 1991).
Regulation o f PTHrP prod uction in neoplast ic and non -neoplastic tissues appears to differ
in different tumours and tissue:types. For example. elevated extrace jfular calc lum levels lead
to decreased PTHrP produ ction by both normal.and malignant keratin ocyte sin vitro (Lowik
CW et al, 1992 ). but increasedproduct ion in a rat Leydig cell tumour model of HHM
(Rizzoli R and Bon jour JP. 1989). In addition. I,2S-dihydroxyvi tamin D) increased PTHrP
product ion in normal hurnan keratinocytes (K.remcI" R el aI. 199 1). but inhi bited PTHrP
mRNA express ion in a hurnan C<e Uline derived from a med ullary thyroid carci noma (Ikeda
K et 01.1989). The molecular basis involved in tbe controlof PTHrP produ ction is unknown
in most tissue type s.
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PTH rP expressice bas bemsho"U to be regula ted by multiple factors ina variety of tissues.
Of the known regulators ofPlHrP. glucocorticoids most profoundl y down -regulate PTH rP
expression and decre ase mRNA and protein produc tion [Lu C et af, 1989 : Gla tz JA et al,
1994). Glucoc orticoids are steroid hormones !ha t KgUlate the metabolism of glucose and
other organicmolecules. Dcumcthasone ,a syntheticglucocorticoid.,decreas.es the expre ssion
or PTHrP mRNA by about 70% (Glatz JA et ai , 1994) . 1,25 ·D ihydro,.;yvitam in DJ is the
metabolicall y act ive fonn ofvitamin D (DarwishH and DeLuca HF. 1993)and it can enher
up-regulate (Merryman n et oJ, 199 3) or down-regulate (A be M et af, 1998 ) PTHr P
expression. Estrogen ( l1~iol) has been docwnenled to increase PTH rP gene
expression in immortalized human ectoccrvicaI cel ls (Rahim tuJa M and Kaiser SM,
submitted), whe reasPTHrP secretion was inhibit ed in the presence of estro gen in an estroge n
recepto r-po sitive human breast eercerceu line, KPL·)C (Kurebayashi J and Sonoo H. 1997).
The effects on expression o f the P'THrPgen e by these hormones are both dose- and ume-
de pendent. PTHrP has also been reported to be regula ted by other facton including seNITI
(Kremer R et al, 199 1). epidermal growth factor (Heath JK et al, 199 5). cyclohexi mide
(Allinson ET and Drucker OJ, 1992) and pho rbo l es ters (Redan S8 et af , 19 89). Although
the biological signi fteanee of these regulators has not been fully eval uated. some of the
functional consequences of their actions o n PTI-lrP prod uct ion in various tissues have been
addressed .
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1.9 PTHrP PHYSIOLOG Y
The function and physiological rolesofPTHrP can be classed into three broad categories: ( I)
PTHrP appears 10 stimulate uansepi!helial calcium lransport in a varie ty of tiss ues,
including the rmaJ tubule (Philbrick WM et al , 1996) and !he place nta ( Rodda CP et al ,
1988) . (2 ) PTHrP is a smooth muscle relaxant ina broad range of tissues. including urinary
bladder (Yamamoto M et al . 1992) and vascular smoolh muscle (M ok I I et al, 1989 ). (3 )
PTHrP is involved in the regulauonof growth and development. PTHrP affects proliferation
(Kaise r SM el a l. 1992) and differentiation (Kaiser SM er ai, 1994) in many cell types ,
Disruption o f the PTHrP gene (Karaplis AC et aJ, 1994) is leth al in fetal or immediate
postpartum life, indicatingthat PTHrP is an important.sometimes necessary .developmental
factor .
1.10 PTH r P AND MODULATI O N OF CELL GROWTH AND DlFFERENTlATIOS
Antisense RNA techno logy is a powerful tcc l wjuch can be used to block the expressio n o f
a targeted gene with high specificity (Ho lt IT et al, 1986). This method was employed by
Kaiser SM et oJ (1992) to investigate the possibil ity that PTHrP may be involved in the
modulation of cellular growth in keratinocytes. The hwnan keratinocyte serves as a paradigm
for autoerinelparac rine regulation inasmuch as it has the capac ity 10 produce a number of
factors that can then modulate function through the: interaction of these factors with their
respec tive receptors. An established hwnan keratinocyte cel l line. HPK 1A. was shown to
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overe xpress PTHrP. In this model . antisense RNA bloc ked the productio n of endogenous
PTHrP and resulted in growth stim ulatory effects . Tha t is. antisense- infected cells
demonstrated a sho rter dou bling: time. an increase in eH]-thym idine incorporatio n and a
greater proportion o f cells were in the S (synthesi s) phase of the cell cycle compared to
control cells (Kaiser SM et at , 1992).
The same antisense technology was used to assess the potential role of PTHrP in
d ifferenti ation of keratlnocytes by Kaiser SM et al (1994). HPK IA cells have a number of
well-characterized maturation indices which are sequentially expressed and indicate
keratinocytedifferentiation. Th e ca pacity of PTHrP to modula te keraunccytedlfferemiarion
was examined by a.ssessing: ( I) the production of high molecular weight keratins. (2) the
expression of transglutaminase. a membfane..bound kerat inocyte enzyme that cata lyzes
prote in-protein cross- linking to form cornified envelopes . and (3) the product ion of
involucrin, one of the precursors of the envelope , in the absence of endogenous PTHr P
production (Kaiser SM et at, 1994 ). There was a reduction in the production of high
molecular weight keratins. as \\01:11 as transglutaminasc and involucrin, in the absence o f
endoge nous PTHrP prod uction . Tbese data suggest that endogeno us PTHrP inhibited the
express ion of markers of kerati nocyte differentiatio n and., therefore . in I.hese estab lished
keratinocytes. endogenous PTHrP acted to enhance differentia tion (Kaiser SM et al, 1994) .
Therefore. antisense-mediated inhibition of PTHrP prod uction has shown that PTH rP can
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mod ulate the growth of normal (Kmna Rei al; 1996b) and trans fected ce lls (Kaise r SM et
al, 1993; KaiSC1" SM et al, 1994 ; RabbaniSA et al , 1995).
1.11 HUMAN PAP lU.OMAVlRUS
TIle pap illomaviruses are a grou p of smal l DNA viruses associated with benign squamous
epithel ial turnouTS in higher vert ebrat es . Human papi Uomavirus (HP V) infection is quite
common in women and is c1eatl y the major risk facto r for cervical intraepithelial neopl asia
(C IN) and invasive cervical canc er . II is in the most estrogen-sensitive cells of the genital
tract that papillo ma virus les ions and their malignant seq uelae usua lly occur (Aubom KJ et
al. 19(1 ). HPV DNA has been detec ted in 80"/0 to 90% of high-grade squamous
inua epithcl ial lesions (SI Ls) and invasiv e ccrvical cancers (Duerst M el al , 1991 ). More than
70 different strains ofHPV have been jdenufied, and spec ific subtypes have been assocla ted
with a greate r risk of progression 10 dysp lasia and cervical canccr(Montcro JA et 01. 1997) .
HP V types 6 and II prefeTentiaJly induce benign proliferative changes of the ep ithel iwn
(cond)' lomata acuminata), whil e others such as HPV types 16, 18, Hand 35 are associated
with prccancerous lesions and squamous cell carcinomas ( Duerst M et al; 1991) . Usi ng in
situ hybridization. Hellbe rg D et oi (1993) found tha i 75% 0(201 cervical punch biopsies.
whic hshowcdCIN les ions o n histology.werei nfected with HP V. HPV 16. 18 and 33 were
found in 33.6%. 12.5% and 8,5%, respect ively, of the HPV lesions. Using the same meth od .
Pilla i MR et al (1998) obse rve d a signi ficantcorrelationbetwcc n the presenceofHPV 16 and
"
high-grade squamous intraep ithelial lesions (Silt) or invasive cancer. In another study , 47
patients "'i lh cervical carcinoma. 55% were infec ted with HPV-16 and 40% were infec ted
with HPV-IB (Konya J et al , 1995). The se studies support the association of HPV with
cervical cancer.
The E6 gene. from cancer-assoctared HPVs. has been shown to be involved in the
oncogenicity of HPV - 16 . The £6 protein is most co mmonly detected in bigh--gradcSILs and
cervical tissue expressing either HPV 16 or IB {Ra pp l et oJ. I99B). This pro te in is
produced by the high-riskHPV types ( 16 and IB)and can bind to and inactivate the tumour
suppressor protein p53, leadin g to dysn:gulated proliferation and defecuve apcpt csis. thus
faciliLUing twnow' progression (Pillai MR et al , 199B).
1.12 CERVIX AND TIlE lNFLUENCE OF STEROID HOR\10SES
The cervix is a specia lized region of the uterus that undergoes an intricate process of
proliferation and differentiati on under the influence of steroid hormones. It is one of the
target tissues of the sex steroid hormones, progesterone and estrogen. and is subject to
control by these ste roids. The human cervix is lined with three types of epithelia: the
ectocervi x, endccervix and thejunction betwee n these two regions, thc transformation zone
epithelium (Sun Q et aJ. 1992). TheectoeerVtcalepithel ium is further divided into three
zones: the basa1 zone , containing stem and parabasal cells; the midzone containing more
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mature cells; and the superfi cial zone containing the highly differentiated. granuJar cells
(Gorodeski 01 er oJ.1990 ). Physiological ly.sex stero ldhocmones are closely assoc iated with
the gro \l,'th and differentiation of me cervical epithelium (Khare S et a f. 199 7). During the
menstrual cycle. the ectocervical epitheli um undergoes a cyclicchange in differenti ation that
is corre lated with chan ges in the circulating level s of es tro gens and prog esun s (Go rodeski 0 1
et a/. I990).
The squamousepithelium of the uterine cervix po sses ses specific binding pro te ins with high
affini ty for both estradiol and progestero ne. kno wn as estroge n receptors (E R) and
progesterone: recept ors (P R). respecti vely (Cao ZY et ai. 198 3). Biochemical and
inununohiSlOChemical srud ies have Mlentified ER and PR in cerv ical epithelium (Gaton E et
of. 1982: Fujiwara H et ai. 1997). Estrogens pro mote cervical gro wth and differentiation.
whereas proges tins inhibi l maturation oCtile eetocervical epuhe llum (MacingaD et al , 1995).
The ectoce rvical squamous epithelium is there fore a sex-ste roid dependent t issue whose
pro l jfera rion and di ffere ntiation are assumed 10 be regulated by sex steroid ho rmo nes via ER
and PR(Fujiwara H et a/ . 199 7; Kanai M et ai , 1998 ).
1.13 RATIONALE AN D PURPOSE OF TH IS P ROJ ECT
The majority of human cervical neoplasms are cl ass ified as squamous cell carc inomas (90%)
(White JO et al, 199 2) and the remaining 10"/. of tumo urs show a mixed squamous/gland ular
or pure glandular differentiation pattern (Dunne FP et 0/ . 1994) . Cervical squamous
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carcinoma is a phe notype which has not conventionally beenconsidered to be stero id-
honnone responsive (Whi te JO el oJ, 1992) . HO" -CVCf. the human squamous ccrvic.aI
carcino ma cell line . HOO-I. was found to be responsi ve to steroid hormones (Whi te JO d
al, 1992). This sugg ests the possibility that endocrine therapies may be of benefit in th is
disease.
A recent study has suggested that cancers of the cervix exhibit a high incidence of PTHrP
expression as detected by immunocytoc hemistry . In one investigat ion of 121 patients. 63
of whom had cancers of the cervix, vulva or vagina. 75% exhibited positive immun ostainin g
for PTHr P (Mc Kenzie S et 01, 1994). Of the remainder. which comp rised endometrial
cancers and Mulle rian duct turnouts. the only PTHrp.po sitive cancen wer e those exhibiting
a squamo us phenotype . In anothe r study by Liapis H el al (199] ). 9]% of squam ous cell
carcmomas of the ce rvix sho"'Cdmoderate to stron g cyto plasmic immunoperoxidasestaining
for PTHr P. Dunne FP et a/ (I994 ) performed imm unohistochemical staining and in silu
hybridization on invasi ve cervical twnoUIS. In this study . 10 of 10 and 16 o f 16 tumo un
examined were po sitive for PTHrP mRNA and Pn-trP peptide, respecti vel y . Kitazawa S
et al (1992) found that 96% of invasive squamous-cellcarcinoma:swm: posi tive for pmrP.
regardless of the patients' serum calciwn levels. The y also found that in eIN, including
kc ilocytic atypia, 76% of'caseswere pos itive for PTHrP as well. Collective ly.these stud ies
strongly sugges t a role for PTHrP in the oncogenicity of cervical tissue.
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SquamolDcarcinomasarc the prototy pical PTHr P·producingtumowsand the most common
cause of HHM (Burtis WJ et aJ, 1990). Some reports have indicated that although
approximately one third of tumours com plicated by malignaney-associared hypercalcemia
are of squamo us cell origin, this complica tion is relatively WlCOmItWn in gynecologiccancers
{Tait Dl elol. 1994 ) compared to othC'rmalignancicssuc:has squamousceil iungeatcinomas
or breast cance rs. Other reports have indicated that gyneco logic neoplasms are frequently
associated with hypercalcemia(Bockman RS, 1980; Holtz G, 1980). Despite the conflicting
evidence, since PTHr P is believed 10 act in an autoerine/paracrinermtraerine fashion to
modulate functions other than the mobilization of caJciwn. we have investigated the
regulation of its production and action in a cervical cancer cell tine .
In this projec t, the CaSki cell line. which serves as a model for the study of cervical
carcinoma. was employed. This cell line is derived from. an epidennoid carcinoma of the
cervix (Patillo RA et al, 1977) and is a well characterized squamous carcinoma cell line
(Grerunan S et al, 1988). The CaSki line contains over 500 integrated cop ies of human
papillomavi rus 16 (HPV.16).
"Thepurpo se o f this project WOlS to investiga te the regulation of expression as well as the
secretion of PTIlrP in response to various growth factors and hormo nes. and in particular
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to study the effec ts of thc sex steroid honnoncs, 17fkstradiol and progcsterone . Wc have
compared the TCSullSobtained with these mal ignamcclls to data previously obtained inHPV.
16 immortal ized ce lls (HEC· 16).
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CHAPTER 2: MATERlAI-S Af'\Il) METHODS
2.1 CEUOJLTURE
The hwnan epidennoid cervical squamous carcinoma cell line. CaSu. was obta ined from
American Type Culture Co llectio n (ATCC, Rockvi lle. MO) . Squamous cell carcinomas
express a spec ific membraneantigen phen otype including keratin pearl formation. a posi tive
reaction to pemphigus antigen as ....ell as to pemph igoid antigen (Care y IE el 01. 1983;
Grossman B et al; 1984). CaS ki cells also express this rypica1 phenotype (Grenman S el 0/ .
1988). CaSki cells weregrown as monolayer:son 75 and , 7S cm 2 tissue culturetlasks(VWR.,
Mi ssissauga. ON ). Cells ....ere maintained in gro....th medium cons isting of Dulbecco's
Mod ified Eagle Med ium (OMEM . 90%. v/v) w;tho ut phenol red (Life Technologies.
Bur lingt on. ON ), fetal calf serum (FC S. 10% v/v; life Technologies) and Ix anti biotic-
ant imycot ic (Life Technologies) . The Ix antibiotic-an timycoti c was used 10 pre ven t
co nramineuc n of the cd! line from bacteria, fungi and ye ast. The antibi ot ic-ant imycotic
contains 10.000 units of penicillin (antibiotic). 10.000 ""g of stre ptomycin (antimyco tic) and
2S ""gof am photericin BImL utilizing penicillin G. strep tomycin sulfate and amp hotericin B
as Fungizo~. OMEM was steri lized by filtration through a 0.2 ""filler (Nalgene. VWR).
Cell s were grown at 370C in a hwni dified aunosphcre o f S% C~ and 95% air.
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The cell line was maintained by passaging cells once or twice weekly. Ce lls were washed
with phosphate buffered so lution (PBS) and trypsinized "'i th 5". trypsi n in Hank 's
Balanced San Solution (HBSS) (life Technolog ies). Cells wcre <:entrifug ed at 200 ltB for 5
minutes . the superna tan t was aspirated and the celt s wese replaled onlOtissue culture flasks
at a dens ity c f approxlmately 2 x 10' cellslml of fresh mediwn . Cells were again incubated
and were aJlowed 10 grow until 70% contluern, At 70% confluence. 75 and 175 <:m 2 flasks
contained approximately 6.5 x 10" and I.S x 10' «lis. respectivel y.
Stocks of CaSki cells were stored in DMEM + 10% FCS containing dimeth yl sulfoxide
(DMSO ) ( 17%. vtv, Fisher Scientifi<:, Monlleal , QC) in a -70 De freeze r or und er liquid
nitrogen . Fresh ly trypsiniz cd cells were pelleted at 200 x8 for S minutes and re suspende d
in the mcd iumlD MSOmixture at a concentration of 2 x 10" cellstmL A I ml portionof this
suspension was tr.u1Sfened to a 2 mL Coming cryogen ic vial (Flsher Scientific) and stored
at -70OCovemi ght before placing into liquid nitrogen . To retrie ve a stoc k. a vtercfcells was
thawed immediately at 37 OC and pelleted at 200 ltB fOT 5 minutes . The pe llet was
resuspended in 10 mL of groWlh medium and plated on to a 7S cm! tissue culture flask .
All stock so lutions were prepared by disso lving the horm one! growth facto r stoc k. reagents
in lOO"/oethan ol. Ethano la I O. I% or less has been shown not to effect growth rat e. 'l iability.
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or satura tion of ce lls over the dW'ation.o f experiments (Grenman S el ai , 1988). Epidermal
growth factor (EGF , Sigma, Oakvilje, ON) was prepared as a stoc k solution at a
concentratio n of 100 ng/mL Progesterone (Prog) , 17JH;stradi ol (E z) and dexamethasone
(Dex) (all from Sigma ) werepreparedas stoc k solutions at a concen trationoflO·J M. 1,25·
Dihydroxyvitamin OJ ( 1,25 (OH) l 0 J) was a kind gift of Dr. M Usko kovic (Hoffman-
LaRoche , Nutley , NJ) and as tock solutio n was smi lari ly prepar ed. All stock so lutions wen:
stored at _20 °C until use and were dilut ed in growth medium prior to use in ex periments.
2.1.3 DoM' Response EJ.pe:riraenls:
CaSki ce lls were seededin 6--wellplates in D MEM + 10% FCS at a den si ty of 2.4 x 10'
cells/we ll. During plating, the cell suspens ion was freque ntly and lhoro ug hlymi.xed to ensure
a unifonn cell dens ity in each well. When the cells had adhered to the wells and were
appr ox ima tely 60% co nfluent (about 24 hours ), the gro wth mediwn was removed and
replaced wi th serum free DME M for 24 hours . Follo wing this. at time zero . cel ls were
trea ted with vary ing concentrations of the:factor under investigation. and incubations were
continue d . At spec ified times after treatment, cells were harvested. Ce lls were tryp s inizcd
with 1 mL o f 5% Il)'pS ln (in HBSS), a 200 ~L portio n of the trypsinized ce ll solution was
removed and coun ted . The 200 JIl. ce ll samp le was placed into 20 mL of Iscton III
electro lyte solution (Coulter Corporatio n, Miami , FL) and counted in a Co ulte r Co unter
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(Model ZBI. Coulter E lectronics. Bedfcrdshire, UK). The remaining cells were centrifu ged
31200 xg for 5 min utes . rinsed with ice co ld PBS and stored at .70 oC for subseq ue nt RNA
anal ysis.
1.1.4 T im e Course [JlpU ime .,s:
CaS ki ce lls were seededin 6- well plales in DM EM + 10-....FCS at a den si ty of 1.5 x 10'
cellslmL and inc ubated for 24 hours . During platin g, the cell sus pensio n was frequently and
thoroughly mixed to ensure a unifonn cell den sity in eac h well. When the ce lls were
approx ima tely 50% co n flue nt (at 24 hours), the medium was remo ved and replaced with
serum free DM EM for 24 hours. At time zero . cells wer e trea ted with set conce ntrations of
factors. At speci fic tim e points. cells were trypsinized a 200 j.tl. portion o f the uypsini zed
cel l mixture was removed and counted . Tbe 200 ~L cell sam ple was placed into 20 mL of
Isoecn III e lectrolyte so lution and coun ted in 3 Coulter Counte r. The remai nin g ce lls were
cen trifuged at 200 xg for 5 minu tes, washed wi th ace cold PBS and stored at · 70 "C for
subseq uent RNA anal y sis.
2.2 R1BOl\rl'UCLEIC A C ID (RNA ) ANALVSIS
Cytoplas mic RNA was iso lated using the No nidet P-40 (N P.40 ) method of extraction
(Go ugh NM. 1988). Pe lleted ce lls were thawed . Ce lls were res uspended in 400 fJl.of Np-
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40 lysis buffer cons isting of cold 10 OL\.f Tris-HCI (pH 7.5). 0.15 M NaCI. 1.5 mM MgCll
and 0.65% NP-40 . The cel t suspen sio n was transferred to a microfugc tube and centrifuged
in an Eppendorf microfuge (Model 54 15C, Brinkmann Instrum en ts Inc ., Westbury, NY) at
1000 rpm fo r 5 minutes at 4 0c. The supernatant was transfe rred to a microfuge tube
containing 200Jll. urea buffer(7M urea. 1% SOS, 0.35 M NaCI. IOmM EDT A, IOmM
Tris-HCI (pH 7.5) pl us 400 j,lLof pheno l:chIoroform :i.soam yl akohol(SO:50 : I, v/v /v ). The
phases were mix ed by vigorous shaking for ]0 seconds and sto red at . 70 oC for a minimum
of 1 hour . The tube s were then thawed at room temperature centri fuged at 14,000 rp m for
5 minutes. The aqu eous phase (uppe r layer ) containing the RNA was transferred 10 a new
microfuge tube and the RNA was prec ipitated by the addition o f 40 Ill- of 3M sodium
ecetare (p H 5 2) and 1 mL ice cold 100% ethanol and this was sto red ai_70 °C. RNA was
eecovered by ccntrifu gationat 14,000 rpm for ISminutes . lbc liquid was asp irated and the
pellet was was hed with 1 mL of75% cthan ol. Tubes were ce ntri fuged at 14,000 rpm for 5
minutes. the ethano l was againasp irated and RNA pellets were dried using a Speedvac
(Savan t Instruments Inc. , Hicksvill e. NY) for 4 minutes . Recove red RNA was disso lved in
10 j,lL o f 0 .1% DEPC treated wate r. The coecentrauc n o f RNA was determined
spectrop hoto metrical ly and the RNA was stored at . 70 oC until No rthe rn anal ysis.
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2..3 Q UAATITAnON or RN A
To dete rm ine the quantity o f recove red RNA, the RNA was heated in a 54 °c water bath
(Mod el 180, Precision Scienti fic, Chicago , lL) farS minutes. The tubes were immed iate ly
placed on ice for 5 min utes to prevent secondary and tertiary fo lding wi thin the RNA. A 1
J.lL portio n of the RNA solution was diluted 1:1000 (wi th oEPC treated wa ter ) and the
optical dens ity (0 0) ""'35 determined in a Beckman spectro pho tometer (Model OU-64 ,
Mandel Scie ntific, Guel ph. ON) . The 0 0 260was used to calc ulau: the conce ntra tion o f
RNA in the sampl e. An 0 0260 of I corre spond s to approxima tely 40 J.1gImL for single -
stranded RNA. The 0 0 ratio 2601280 pro vided an est imate of purity of the nucleic acid
solution. Pure RNA solutions have an 0 0 2601280 rano c f 2.0 (Mania tis T and Fritsc h EF,
1987) .
2.4 ELECIRO PHORESIS or RN A
RNA was size.fractionatedby eleetropbores ison a 1. 1% agarosc-formaldehydegd. T we nty
J.li o f RN A was combined with 3.2 parts of sample loading buffer containing 31%
formald e hyde (21%, vtv), lOX MOPS (13%, vtv, 0.4 M MOPS , 0.1 M sod ium acetat e pH
7.0, 10 mM EDT A pH 7.5) and fonnamide (66%, v/v). The formamide had been deionized
by stirring with a mixed bead resin. AG SOI·X8 (BiG-IUd. Herc ules. CA ), for one hour .
RNA was denatured by incubating the tube s in a 65'1: water bath for 15 minutes. The tube s
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were quickly chilled on tee for 5 minu tes and centrifuged brie fly . Two ~ of RNA loading
buffer (50% glycerol. 0 .25% bromophenol blue and l()'lene cyano l FF and I m.\t EDTA. pH
8) and 2~ of ethidi um bromide(0 . I mgImI) \\o~ added to each sam ple and loaded onlo the
gel. Electrop horesis was condw;:ted at a co nstant voltage (20 Vo lts) in I X MOPS buffer (40
mM MOP S. 10 mM sodium acetate pH 7.0. I mM EDTA pH 7.5) for about 16 hours
(overnight). Following electrophoresis. RNA was visualized using ultraviole t (uv)
transilluminatio n to ascertai n tha t the RNA hadbeen electrophoresed for a sufficient time.
That is. electrophoresis was stopped whe n the 18S and 28S ribosomal RNA (rRN A) were
ap proxi mately 2 cm apart . The locat ion of the l8S and 285 ribo somal RNA (rRNA ) were
determined by photographing the gel under uv light gel using the Chemilmager 4000 (Alpha
lnnorech Corporation. distribut ed by Canberra- Packard Canada Ltd., Montreal , Qq.
2.5 NO RTHERN BLOT ANALVSIS
2.5.1 Gel T nasfer:
Follo wing electrophoresis. RNA was transferred to a nylon membrane (Hybond· N.
Amers ham Canada Inc.• Oakvil le, ON) by capillary blotti ng (F igure 2.1). Brie fly. the
mem brane was wened in 0.1". DEPC·rreared water and soak ed in lOX SSC (1.5M sod iwn
chloride. 0. 15 M trisodium citrate , pH 7.0) for at leas t 15 minu tes prior to the transfer . A
support was placed inside a large dish whic h was filled with lOX sse to the level of the
40
bottom of the support. A piece o f l ei blot papa (Mande l Sc ien tific). ....tti ch was cut wider
than the gel and Ioogenough to dra w up buffer so lution from the reservoir, wasplaced across
the suppc n . The well s and the top righ t hand comc:rof the gel ....ere cur and removed . The
gel was placed on the gel blot paper in an inverted position . The wet nylon membrane was
then placed on top of the gel and the comer of the membran e was cut to match the corne r
from the gel. Air bubbles wen: removed by rolling a glass pipe t over the surface of the
membrane . Cellophane wrap was placed around the nylon mem brane to pre vent evaporation
of the lOX sse so lution. Neltt, two pieces of gel blot paper , wened in 2X sse (o.) M
sodi um chloride.30 mM uisodiurn citra le,pH 7.0), wereplacedon top o f the membrane and
again air bubb les were remo ved . A stac k of paper towe ls, whic h acted as a wick. was placed
on top of the gel blot paper . Next, a glass plate was placed on top of the paper towels and
finally. a weight of 500 grams was placed on the stack of paper tow els. The tran sfer was
allowed to take place for I8·24 hours . The filter was then air dried and baked at 80 °c for
two hours to fix the RNA Onto the mem brane. The positions of the 18S and 28S rRNA were
marked on the nylon membrane and were used as internal marken. . Tbe fillers were then
stored in sealed bags at 4 OCuntil required for hybridization .
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Figure 2.1 : Diagramatic represcnlation of a capillary blotting apparatus.
(Ada pted from Mmiatis T and Fritsch EF. 1987)
1.5.2 ~DNA Probes:
Hybridization was carrie d out with either a hwnan PTHrP or a rat cyclophilin probe . The
PTHrP probe was obtaine d from an SP65 (Promcga) in vitro transcription plasmid into
which was subclcned a 531-basc pair Sacl-Hindlll restri ction fragme nt encodin g exon VI
(cod ing regio n) of the PTHrP gene (Kremer R et ai, 199 1). The rat cyclo phil in probe was a
BamH I restricti on li'agmcnt of ral cyc lophilin from plasmid plBI 5 (Daniel son PE et 01,
1988). ONA probes were labeled using the randomprimer method described in section 2.5.3.
1.5.3 Random Prillllrr !'tIlrtbod Labdin&:
Double stranded DNA was labeled using the Random Primers DNA labeling kit (Life
Technologies) . The reaction was performed follo",; ng the manufactw"er's instruct ions and
using the reagents provided in the kit. The react ion mbe co ntained the follow;n g reagents :
Probe DNA (PTH rP or cyclophilin)
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25 ng
dA TP solution
dG TP solution
dITP so lutio n
Random Primer Buffer Mixture
[a.J 2PJdCTP (>3 .000 Cifmmol)
K1eoow fragment
Distilled water (to a final volume of 50 Il l )
{a .1!P JdCTP was purc hased from Amersham {Mississauga, O N) . The reaetWJntube was
incubated for 2 hours at 25 OC and the reaction was terminated by the addition of 5 ilL of
Stop Buffe r. SpilH: olwnn clvomatography (secti on 2.5.4) was perfonn ed [ 0 remove
unin corpor ated dCTP .
2.S.... Sp in.Colu m n C bro matogra p hy :
A I mL syringe (Becton Dickinson. Mi ssissau ga, ON) was plugged with fibreglass (Co ming
Glass works, Co rnin g, NY) and was placed inlo an ernpty IS mL polystyre ne centrifuge
tube (F isher Scienti fic) . SephadexG-50 (Phannacia)s luny equi libratedin TE buffer ( IO mM
Tris- HCI, I m.\.1 EDTA . pH 8.0) was added to the syri nge . Thi s was centrifug ed at 1000
rpm (2008 ) in a Sorv all centrifuge (Mode l RT6000D. DuPont. W ilmington . DE) at 4 Dc for
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5 minu tes . More Sephadell G-50 slurry was added and centrifugation was repeated unti l the
packedcolwnnhad a voIwne ofl mL. Thi s was followedby the addition of 1 mL TEBuffer
(pH 8.0) and the co lumn was again centrifuged. "Thelabelltng reaction mixture (SO JL1.) was
the n applied to the packed co lumn and.centrifuged fOl" .smin utes . The effluent (con taini ng
J2P_labelied DNA ) was co llected in a microfuge tube . A 1 ~L portion of the labelled DNA
probe was placed into 10 mLo f ScintiVersc scinti llation fluid (F isher) and specific activity
(cpml~L) was estimated by scintilla tion counting (Model LS 380 1. Beckm an Instru ments.
Fulle rton, CA) . Tbe rad iolabe lled DNA probe was stored at _20°C unril used.
2.5.5 Prrhybrid ization :
The membrane was placed ont o a nylo n mesh (8 H-9109, 8 MYCan Scientific Inc .•
Miss issau ga, ON) and soaked brie fly in 2X sse (0.3 M sodium chloride and 30 mM
trisodi um citrate. pH 7.0) . The membrane and mesh stac k were rolled into a tight spiral and
inse rted into a hybrid izatio nbonle. Prewanned(42 OC) prr hybridizatio nbuffer solution was
added to the bottle with a minimum volwne of 125 flllcm l of membrane . Th e
prehyb ridi zation solution co ntai ned :
sse
Denhard t's solution
20%SDS
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6X
SX
0.5% (v/v)
Deionized formamide
0.1% DEPC· trea ted water
Denatured sonicated salmon sperm DNA (Phannacia)
50% (v lv )
5.5% ( vlv)
IOO)lgfmL
De nhatdt's solut ion consisted of Sg Fico ll (Type 400 . Pharmacia ), 5g polyviny lpyrrolidine
(Sigma) and Sg bovi ne se rum albwni n (Fraction V, Sigma)d issolved in water 10 a to tal volum e
o f 500 mL. The filters were incubat ed and constantly ro tated for 4 hours at 42 °C in a Tek
Star JR hybridiza tion oven (8ic/ Can Scien tific ).
1.5.6 ffybridizatioa with the Jl P-bM Ied DNA proM:
Following ptehybridizat ion , RNA was hybridized wi th either a PTHrP « cyclophilin Ic -
l1p]dCTP labeled DNA probe at a spec ific activity of approximately 1.0 11:10" cp mlmL
hybrid ization solution. Hybrid izatio n was performed in the same solution used for
prehybrid lzario n. Imm edia tely prio r to use, probe DNA was denatured by bo iling for 5
minute s and was then cooled on ice . The probe was add ed to the hybridiza tion so lut ion and
hybrid ization was carried out for 24 to 48 hours at 42 ' C.
2.5.7 W ashi ac of . he blot5:
Following hybridization, the blots were successiv ely washed as follows :
I X sse. 1% SDS for IS minu tes at room temperature (Rn
O.S x sse.o.s%sos for-IS minutesat RT
05 X sse. O.S% SOS for 15 minutesat RT
0.1 X SSC. O.I % SDS twice for 15 minutes at RT
0.1 X SSC. O.) %S OS for 30 minutesat ss-e,
Membranes were then autorad iographed as described in the following sectio n,
2.5.8 Au.ondiognpb)' :
After was hing. the blot was sea led in a plas tic bag and expo sed to Kodak X-OMAT x-ray
film (picker Intern ational. Montreal. QC ) in the presenc e of two intensifying screens at -70
°e. The exposed film was developed in a Kodak X...QMA T film develope r.
2.5 .9 Dnsito me trk Aaa.,..,b :
Quantitation of the signal was achieved by performing spo t dens itometry using AJpha Ease
Software (Can berra Packard Canada.Montre al. QC). Intensity dens itometric val ues we re
determined for the rad ioac tivi ty on the autoradtographs. Quantitation wascom pleted " i thin
the linear rang e ofdensi tometri c response to the rad ioac tivity o n the blot.
2.5.10 Rep robill&No rt br rll Blob :
The [a·:UPJ-labeled DNA probe was stripped fro m the Northern blot prior to reprob ing the
membrane with othe r [a .J2P]_labeled probe s. To remove the old pro be , a boiling solution of
0.1% SOS (w /v) was poured onto the blot and aJlowed 10 cool at room tem perature. The
blot was then rinsed in 2X SSC (0.3 M sodium chloride, 30 roM Trisodium ci trate, pH 1.0)
and a Ge iger Coun lCJ'(Mode l 44- 9, Lud lum Measurements Inc .•Sweetwater. TX) ....as used
to asce rtain removal of the previous pro be.
2.6 RA Dl Ol MMUNOASSAY (RIA) or IMM UNOREACTI VE PTtfrP (iPTI l rP)
2.6.1 Co llrd io D or sa m ples :
Conditioned culture mcdi um. 1.5 mllwell ine-welt c tester plates. was removed from the wells
at timed interval s. AJiquots of SOO~ wer e frozen immedial ely and stored at · 70 °c for
subsequent measurement of PTHrP by rad ioimmunoassay (RIA). Cells were tryp s inized
and a 200 I!L sam ple of the trypsinized ce ll mixture was co unted in a Co ulter Counter to
determine ce ll num ber . Before r.di oimmunoassay, the samples of conditioned medium were
evaporated to dryness in a Speed vac (Model SVC·IOOH. Savant Instruments Inc.,
Farmingdale , NY) and were subseq uently reco nstitu ted and assay ed (sectiOfl 2.6.6) using
PTHrp(I·34) as a standard .
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2.6.2 Aliq uorinc or Sia nda rds :
Sod iwn acetate (O.OI M)was added 000.1 mg of hwnan PTHr P( I-34) to a frnal volwne of 2
ml. This so lution (also known as the iodination pept ide so lution) was then placed into
disposab le borosilicate culture rubes ( 12 x 75 mm. Fisher Sc ialtific) and dried in a Speedvec.
ThC'sC' a1iquo lS wen: diluted to a final concentration of 25 ng/)1l. by the addi tion of 0 .2M
phosphate buffer (57.7 mL ofNaH2PO~ addcd to 42.3 mL ofNa!HPO~, pH 7.0) and wer e
sto red at _70 °C.
2.6 .3 lodinalion Peptide:
Sodium aceta te (0.0 1M) was added to 0.2 mg of human PT HrP( 1-34 )TyrOto a tinaI volume
of 2 ml. This solution was placed inroculmre tubes anddried in a Speedvac. The aliquolS
were diluted toafinaJ concentrationcr n.t p glpL b)·the add ition ofO.OI M sodium aceta te ,
wi th 2 )lg of hPTHrp(I -34 )Tyropc:r tube, and stored at . 70 OC..
2.6.4 lodinalioD of PTHrPU- .J.4)Tyro : Pnpanlion of T ra cer:
The iod ination peptide was tha wed and dissolved in 100pI. o f 0.2 M Phosphate buffer (p H
7.0). While vortexing, I mCi of 11' 1 was added to this so lutio n. Iod ination was initiated by
the addition of 20 ut. of freshly pre pared Chloram ine T (1.25 mglmL in 0.2 M phosphate
4.
buffet". pH 7.0) and vcete xed for euctJy 25 seconds. Iodinati on \0\'35 terrnina red by lhe
addition of 50 J,1L of freshly prepared or sodiwn metabisulfite (2.5 mg!mL in 0.2 M
phosphate buffer, pH 7.0).
A trichloroace tic acid (T CA) test was perform ed to determine the amount of incorporated
1251. Outdate d blood bank plasma (OBBP; 200 J,1L), and tracer (2 J,1L) were added to a test
tube. Next, 200 J,1L ora 40% TCA soluuonwas addcd to the test tube while vortcxing. The
rube was then cen trifuged at 1800g for 15 minutes . Superna tant and precipitate were
separa ted and bo th were counted in a pnma coun ter (Model LKB-Wallac GammamastcT
1277, Turku. Finland) . 1251 incorporati on was calc ulated as follows:
0"," incoepora tion « l::nm (nr=tn,ta te l x 100
cpm (prec ipitate + supema tam)
If the % incorporation was <30, the iodination proced ure was repeated . Otherw ise , the
tracer was purified on a P·IO co lumn to prepar e for the assa y.
2.6.5 Pnparalio. of P· I DColuma :
Unincorpo rated 1251 was separated by passage throug h a ScphadcxG·50 co lumn as described
by Man iatis and Fritsch (1987) wi th minot modifications . Scphadex G·50 slurry was
equilibrated in DEPC water and poured into a 12 mL steri le disposabl e pipette (Fis her
Scientific) containing a pyrex fibreglass plug at the bott om. A piece of polyeth ylene tubing
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( Becton Dickinson. Pars ippan y, NJ) was placed. at the tip of the 10 mL pipette and was
connected to a fractioncollector(Model l KB Bromma 7000 Ultrorac. S" "eden). The rol wnn
was initially washed with barbital buffer (O.OSM sodiwn barbital. 0.05% thimerosal). Next.
the column was eluted with Barb SlSObuffer (barbital buffer containin g ODBP (:ze/. , vtv).
The trace r was placed on the column and eluted with Barb SlSO. The eluant was collected
in 10 dro p fractio ns. An tubes were counted in the gamma counter and cpm values were
graphed relative to the rube num ber. The first peak o f radioactivi ty was indicati ve of the
tracer whereas the second peak represented free unincorporated iodine. The peak tracer
tube(s) were sto red at -20 De until furtheruse .
2.6.6 Assay orIm m u noreac: tin PTH rP (iPTH rP) :
PTHrP secretion was measured using a five day radioimmunoassa y (RIA) . The standard
curve for the RIA was set up in the following manner (Ta ble 2.1):
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Table 1.1: Experimental set up for RIA standardcurve.
T ube Sampl", ODDP PT HrP Barl> PTHr P( 1· 34 ) T~
• S<andMd SlSO Ant ibody (10.000
1:8000 cpmltubc)
1.2.3 B'''''' 300 JiL ioo ut, IOOJiL
4,5.6 Reference 300",- IOOJ,lL lOOIJ,L
7.8 ,9 To tal 1400JiL lOOJ,lL
10· 31 Slandanh 300 ",- 100",- IOOJ,lL
Samp les 300 JiL IOOJiL lOOJiL
On da y I, the standard curve was set up as a duplicate set of 10 seria l dil utions of PTH rP
standard, ranging from 25ng to 0.025 ng tlPTIl rP( I. J4 )per rube. To tal . Refeeeece aed Blank
rubes were used to determine:specific and nonspecifie binding of the ant ibod y 10 the known
standard concentrations of PTHrP . The antibod y "lollS a rabbit polydonai hPTHrP( 1· 34)
antibody and was diluted to a finalconcentrationof I:8000. DB OP and antibody were added
to samp le rubes . All tu bes were vortex ed and stor-edat 4 GC for 2 day s.
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On da y 3. a dil ution of IO.DOO- I2 .000 cpm of m i. labelled PTHrp(I-34)Tyl in IQOrJ.L of
Barb S/50 was added tc all assa y tubes . The tubes were vonexed aad incubated at 4 °c fo r
2 addi tional days.
On day 5. bound and freelUI_labe lled PTH rP( I-34)Ty,o were se para ted . A mixture o f3%
alkaline charcoal and 0.3% dextran in barbital buffer " 'as stilTed foe 30 minutes prior 10 use .
One mL was added to each assay rube except Total tubes (7.8 .9). The tubes were vonexed.
incubated for 30 minutes at 4 °c and then centrifuged for 15 minutes at 3000 rpm . Th e
supernatan t was decanted , supernatan t tube s were corked and the rad ioactivity was counted
in gamma -counter. Bound 12'I_labelled PTHr P(I -34 )TyrO remained in the superna tan t.
whereas free I~ I-Iabelled PTHrP(I-34)Ty? remained in the pe llet . Specific and nonspeci fic
binding were calculated as follows:
Specific Binding (%) =..Rdm!G- ,, 100
Tola! - Blank
Nons pecific Bindin g (%) =~ x 100
Total , Blank
Specific binding >20% and nons pec ific binding of <1"A.must ha ve been achieved in order for
(he standar d curve 10 be used to calculate sample results. Sam p le results were expresse d as
nano gram equiva lents of hPTI JrP(I ·34 )1106 cells. The detec tio n limit o f the assay was 0. 1
"
ng eq hPTHrP(I-J4 ).
2.6.7 SCatisCica l aaalysn:
All resul ts of the RIA were expressed as the ± Standard Erro r of the Mean (S EM) of the
repl ica le delenn ina tions and sutisti cal com parisonsbased on the Sruden t's f lest (two-tai led).
This type of anaJysis was used as it is the standard sta tist ical method used in testing fo r
statistical significance in RIA in thi s field of researc h (Henderson J et oJ. 199 1; Kaiser S M
et al; 1992; Kremer R el oJ. 199 6). A probabi lity value o f <0. 0 1 was cons idered to be
s ignificant.
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CHAPTERJ: RES ULTS
Previous stud ies have demo nstrated thai PTHrP is prod uced by many hiS1Ological types o f
cancer cells as v.ell as being identified in a number ofnorma.Iadult and fetal.tissues . Mor e
specifical ly, in our laboratory, the regulation o f PT HrP has beenexamined in respo nse to
known (EG F, dexamethasone and 1,2S-dihydroxyvi tamin DJ ) and potential tissue-specific
(p rogesterone and 1 7~strad iol) regulators in an ectocervicel cell line immortal ized wit h
HPV· 16 (HEC-16) (Rahi mtula M and Kaiser SM. submined). This system is part icu lar ly
interesting in view of the role of PTHrP in the regu latio n of cel l gro",th an! differen tiatio n
through its autocrinc and paracrinc actions. The ectcc ervical epithelium isunique in that it
undergoes acycli c change in diffcrm tiationdurin g the menstruaI cycle. Thus, in ec tocervical
cells. tissue levels of PTIf rP and thus the:growth and differentiation of these cells ma y be
regu lated during the menstrual cycle by estrogen and progesterone.
In this project. the human squamo us cervical carcinoma cell line, CaSlci. was used as a model
of late stage oncogc:nesiso f the cervix. The purpo se ofthe experimentswa5 to determine the
regulation of PTH rP in these cervical caretooma cells in comparison n immo nahzed
ec tocervica l cells as well as to the regulation in other ussees. Northern antJysis was used
to assess the effects of various factors on PTHrP mRN A expressio n and ~ hPTIfrP( 1- 34 )
radioimmunoassay was used to determine the effec ts on PTIfr P secret ion in these cervical
S4
carcinoma cells .
3,1 NORTIlER.~ A.~ALYSIS
3.1.1 Dese RnpolI'~ Es.pen.nlts:
Initially, the reguJation ofPTHrP gene expression in response to varying concentrations of
Kn O\\.T1 (EOF, dexamethaso ne and I,2S-dih)'·dro~itamin OJ) and polential tissue-spec ific
regulators (progesteroneand 17f)-estradiol)was examined. These dose-response experiments
allowed the assessme nt of whether the substance under investigation induced a change in
PTHrP mRNA ex pression and, ifso , the concentra tion at which the observed response was
maximal.
Initially, experi ments were carried out in OMEM plus 10"1e FCS. However . varying the
dose of EOF, prog esterone and 171l-estradiol produced maxi mal stimulation of the PTHrP
transcript even al the lowest dose examined. with no further Ircrease in PTH rP mRNA
delectable at higher dose (da la nol shown). Therefore, further experiments with these
factors were performed in growth medium with no added FCS. However , FCS was used in
experiments study ing the effects of dexamethasone and I,2S-dihydroxyvi tamin OJ'
Cells were challenged at 40"" and SO%for the time course and dose response expe riemnts,
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respecti vely . lluough experime ntl tion it was determ ined that the greatest response to FCS
(with respect to PTHrP expression) was seen at this level of confluence (data 001 sho wn) .
3.1.1.1 Kn owa Rqulaton: EGF. Denmetbuone nd 1.2.5-DibydroIYVilamia D):
EGF has been shown 10 ~gulate PTHrP in othe r t issues as weu as in establi shed
ectcc eevical ce lls . Figure 3. IA sbows that in CaSki cells. EG F simil arly produced a dose .
depe ndent increase in PTHrP mRNA leve ls 24 hours after stim ulatio n. with a maximal
increase (nonnalized to cyc lophihn ) at 20 ng/ mL. Figure 3.1B is a gra phical representation
of PTH rP mRN A levels, expressed as a percenta ge of the basallevel. At 2Ong/mL of EG F.
there is nearl y a 4.5· fold increase in PTH rP mRNA levels, compared to basal . A further
increase in the do se of EGF did not prod uce an additionalincn:ase in PTH rP mRNA. Figures
3.1A and 3.3A indicale that , at 14 hours after treatment, both dexame thaso ne and 1,25-
dihydroxyviwnin OJ prod uced a dose-dc:pendenlinhibitio nof PTHrP mRNA. with maximal
effects (normaJ ized to cyc lophil in) observed at 10" M. Figures 3.28 and 3.3B represent
PTHrP mRN A levels (normal ized to cyclophili n) and demo nstra te a So--'. reduction in
PTHrP mRNA levels , exprnsed as a percentage of contro l leve ls, foe both dexamethasone
and 1,25-dih ydroxyviwnin OJ, Inhi bition of PTH rP did nOI increase further with higher
doses of eithe r dexamethasone or 1,2 S-dihydroxyviwnin OJ.
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3.1 .1 .1 Poteatial Tissue SpecifIC Rqub ton: Prnletteroae a a d 17Ji-Estradiol:
17Ji-Estradiol. in the absence of FCS. produced an increase in PTItrP mRNA expression
(nonnalized to cyclophi lin) at 24 hours aft er treatment (Figure 3.4A). A 3.S-fold increase
in PTHr P mRNA, compared to basal , was observed at 10" M and is represe nted graphical ly
in Figure 3.48. Progesterone did not produce a notable change in PTIlrP mRNA express ion
(normal ized to cycl ophilin) (Figures 3.5A and B) at 24 hours . It is impo rtant to note tha t
PTHrP express ion appears to be inconsistent with that o f other basal ce lls. The increase
seen in PTHrP expeess ion is attributed to the fact that there was a IongICt'" exposure time .
3.1.2 Tillie Co u n e Espe:ri lOellts
3.1.2 .1 F.fTec:torcul to" co nditions ODPT HrP mR.~A n pRSsion:
In order to further evaluate the effects of the various factors on pnlrP ge ne express ion. it
was im portan t to dete rmine the effec t of culture conditions . part icu lar ly the presence or
absence of serwn in the culture medium. In the absence ofserwn , (F igure 3.6A) then: was
an increase in PTIlrP mRNA eKpression(nonnaJlzed to cyclophi lin) but nta:<imaJ. 1evels were
not obtained until 4 hours after stimulatio n. Figure 3.68 shows that at this point there was
a 10-150/. increase: in PTItr P mRNA level s (co mpared to that o f time zero ; basal ). At 24
hours. PTH rP mRNA expression fell below basal levd s and co ntinued to decline thereafter.
In the presence of FCS ( I0%). an early incre ase: in m lrP mRNA levels was observed but
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effects were only sligtu and were maximal at 2 hours, as indica ted in Figure 3.7A. Figure
3.7B is a graphical repr-esenla tionof PTHrP mRNA levels, expressedas a percentage o f time
ze ro (contro l). A 25% locreese in PTHrP mRN A expression was SC'CII at2 bours. However,
followin g this, a decline in PTI-lrP maNA levels occurred. wi th a return to conuot tevels by
24 hours . I concluded tha t caSk.i cells did express PTHr P m RNA in the absence o f other
factors. The addition of serum 10 the media caused a further increase:in the amo unt o f
PTHr P mRNA ex presse d by the cells.
3.1.2.2 Errects of EGF, Del.8m etb u onc and 1.23-0ibyd rol. yYUamiD OJ on PTHrP
mRNA Cl.preuion :
These expe riments were com pleted to de tcnn ine if the known regulators of PTHrP would
affect PTH rP producti on In the caSk.i cells over the time course of the experime nt. EGF (20
ngImL) prod uced an ear ly stim ulation of PTHrP mRNA expression ....i th an increase
observ ed at the first time point of 30 minutes (figure 3.8A) . PTHrP rnRNA leve ls
(no rmal ized to cyclophilin) were maximal at 2 hours. Tbe graphical representati on of th is
time course experimen t (figure 3.8B) sho.....s that there is a maxim wn increase In PTH r P
mRNA expression of 4.5· fol d, relative to time zero (basal). PlllrP rnRNA levels decreased
slo.....ly thereafter, but eve n at 72 hours . expression had not fallen 10 basal levels. At 10"*M .
both dexam ethasone (Figure 3.9A) and 1,25-dih ydro xyvitam inD] (Fig ure 3.IOA) produ ced
init ial inc reases in PTHr P mRNA levels, but effects were only slight and were maximal at 2
"
and 4 boura.respeee vety. By 24 hours after stimulation. both~ and 1.25·
dihydroxyvi tamin 0 ) prod uced an inhibition of PTHrP mRNA levels. relative to time zero .
Thi s peraistedto the last time point o f 12 hours. and is indieattdgmphically inFi gures 3.9B
and 3. IOB, respectively.
3.1.2.3 Effuts or 17IJ-Est ndiol . nd Progesteron e oa PT HrP mRNA espressloa :
These experiments were carried out in order to dctennine if the potential tissue -spec ific
regulator'Swould have an e ffect of Pll-lr P mRNA expression over the time course o f the
experime nt. The effec ts o f 1 7~iol (10-& M) were assessed at timed interVals.and like
EGF. increases in PTHrP mRNA expression (nonn aJized to cydophilin) were obse rved at
the ear liest time point of 30 minutes after stimulatio n (Figure:3.11A). Maximal stimulation
o f abo ur a -fotd was observed al 6 hours. which was less than the increase observed with
EGF. By 72 hours. levels of PTHrP mRNA haddecreased. but stillremainede! evatedabout
2-fold above the basallevel (FiiW'C3.118 ).
ProgCS1C1'Of1e: (10" M) also produced an early inaease in PTHrP mR."'lA expressi on
(nonnal iz.edlo cyclophilin) with maximalstimulation at I hour (Figure3 .12A). At thi s time.
pmrP levelswere about 75% above the basallevel. At 24 hours, PTHrP mRNA expressio n
had retumedi c basal levels(Figure 3.128 ). At 48 hours , PTHrP mRNA levels had decreased
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below basal levels.
.J.1 RADlOIMMUNO ASSAY
3.1.1 DoJ~ ResPODS~ E:lp n i.llln ts:
3.2.1.1 PTHrP sec~tio. iD rnpoDH 10 kDo..... ~1.lon: [G..... DuameibuoD~ .Dd
1.zs.. Diby d ro I.YVila Dlia OJ:
These:experimen ts were completed in order to determ ine if varying doses of the known
regulators had an effect on iPTHrP and if so, at wha t conce ntration were these: effects
maximal. At 24 hOlUS. EGF produ ced a significan t increase in iPTHrP levels with max imum
secretion obtained using 20 ng/mL (Figure 3.13). Furthc:r increases in the concentration of
EGF did no t produce a fwthe r increase in iPTHrP sec retion. Both dexame thaso ne and 1,25-
dihydroxyvitamin OJ produced signifICant decreases in iPTIU P secretion with maximal
inhibition c bserved et 104 M (Figura 3.14 and 3.15,respecti\lely). Further increases in the
co ncentration of either deumethasoneor I,25-d ihydro xyvitami nD ) did not resul t in furthe r
decreases in iPTHrP sec retion. These resu lts did confmn that the known regulators did
indeed affect PTHr P secretion in theCaS ki ce llsand the do se at which the maximal response
was observed was de termined for these regulators.
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3.2.1.2 PTH r P s«rehon in rnponse to tiss ue-specific lTgulalors: Progesterone ••d
17jl-Estradiol :
To determine if the tis sue specific regulators had an effccl on iPTHrP. dose response
experiments were carried 0Ul using the two hormones and iPTHr P was measum:1 . Al 24
hows . 17~iol produced asi gnifican t increasein iPTH rP secretion with maximal levels
o bse rved at 10" M (Figure 3.16). Further increasesin the conceneanc ncf 171J-estrad iol did
not result in a furth er increase in iPTHr P secre tion . The amount of iPTHrP released into
co nditioned medium (co rrecte d for cell nwnber) was less than that observed in respo nse 10
EGF.
At 24 hours. progestero ne did not prod uce a signi ticanl change in iPTH rP secre tion,
co mpared to basal leve ls. wilhin the range o f doses used (10 -12to 1 0~ M ; Figure 3.11).
The se results demonstrated lhat only 17l3-cstrad iol affected PTI{rP sec retio n in the CaSki
cells under the co nd itions test ed.
3.2 .2 Ti me d ependcaC d r«ls o. iPT HrP '«RUon:
3.2.2.1 Effed of CDltu re cODdiCionl o n iPTH r P He R lion :
To determine the characterist ics of PTHrP secretion in CaSIQ cell s, we firs t measured
iPTHrP in conditioned mcdiwn removed at timed interv als from cells maintained under basal
6\
conditions (Figure 3.11). That is. experimental results wereobtained fro m cells maintained
in O~EM alo ne . iPTIIr P secre tion did no t increaseuntil 48 hours. rel ative to the b-el at
time zero . Add ition of FCS ( 10%) to the cultures elicited a time dependenl augmentation in
iPTHr P thai grea tly exceeded the increase observed in cells cultured under basal cond itions
(Figure 3.19 ). A statistica lly significan t incre ase in iPffirP was meas ured at 24 hours and
levels o f iPTHrP secretion were higher than those demonstrated und er basal conditions
(Figure 3.18).
3.2.1.1 Ti me COUrK n puimea l' of kn ow. ngulaton or PTJlrP: [GF,
Dnamelba.onc a nd 1 .1~Dibydroq'Vitamin OJ:
Th ese experiments werecompleted 10 det ermine the charac terist ics of PTH rP secre tion in
response to the known regulat ors . The effect of 20nglmL EGF on iPT HrP secretion was
exami ned at timed intervals in the absenc e of Fe S (Figure 3.20). At 24 hours . a peak in
iPT HrP was observ ed with approxi mately a 3·fo ld increase in sec retio n at this time.
compared 10 tim e zero . levels contin ued 10 increase until the last time po int of n hours . In
contrast, both dexamethasone and 1 .25-dihydroxyvi~in OJ produced a dec reased iPTHrP
secretion and by 24 hours., leve ls haddecreased by aboul SO%relative to levels observedat
t ime zero (i n the presence of 10% rcs;Figures 3.21 and 3.22. respecti vely).
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3.U.3 Timlr C OUrH n pnimu fl of rqulalon of PTHrP: 1 '~lrad"l aad
proc nllrrodlr :
To determinctbc chazacteristi csof PTHr P sccm:ion.CaSIci ails were treate d with the tissue -
specific regulalors. The effects of l 7~stradiol (10" M) were also assessed at timed
intervals. and like EGF, increases in iPTHrP secret ion were observed. At 24 hours. there
was a 3- fold increase in secretion relative 10 time zero (Figure 3.23) . iPTH rP continued 10
increase unti l the last time point of n hours.
Progestero ne ( 10" M) dad not cause a significant changc in iPTItrP secretion during the time
course (Figure 3.24). "There was an inc rease: in iPTH rP secretion, how ever. the results were
slight and were: not signi ficant. compared to time zero.
3.3 CAS KI VERSUS HEC·16
My experimen tal resu lts from CaSIci ce lls were compared to those of HEC-16 cells.
Experimental work was carried out on the HEC-16 cells by SM Kaiser and M RahimtuJa
previous to my arrival into the laboratory . Expcrimcnlalrc sul ts from the HEC-16 cdls have
been subm ined for pub lication at the time of the writing of this thesis (Rahimtula M and
Kaiser SM. submi tted ).
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3.3.1 EfI'«ts . rEGF. Du.alll~tbaso.~.I .2~Dib)·dro,.,-vitalbiD 0,. Progesl~roa~ aad
17jl-Esl radk»loo PTHrP IIlRNA ~:lprnsioa :
EGF (20 nglmL ) and 171l-estradiol both increased prnrP mRNA expression with about a
1.5·fol d grea ter iocreeseobserved in the CaSki cells than inHEC.16ceUs for both treatments
(Table ] .1) . An inhibition of PTl{ rP mRNA was presen t in both cd l lines after trea tme nt
\\-ith I.2S-d ihydroxyvitamin 0 ) ( 10'" M) wi th abouta 5O% decreasc in PTH rP mRNA 24
hours after treatment. Dexamethasonc(I O" M) produced a SO"/. decrease in PTIirP mRNA
in CaSki cells however, in HEC-16 cells no decrease was see n at 24 hours . However . a
decrease was observed in HEC·16 cells at 48 hours (Rahi mtula M and Kaiser SM.
submitted). In CaSki cells, proge stero ne ( 10" M) did not produce a signifi cant change at 24
hours in PTH rP mRNA but it produccda 2.s ·foldgmucr increasein PTHr P mR....tA in HEC-
16 cells .
3.3.2 Effects or [ Gr. Dexam eth asone . 1.2S-Dihydr oJ;yvitamia 0 10Pr ogester on e a nd
17f}-Es tradiol ODiPT H r P secr~tloo at 24 hOU ri arte r trutmen t :
Twenty-fo ur hours aftel" EOF (20 ngAnl ) treatme nt, iPTl-t"P sec retion was O.862 ng cqll di
cells in CaSki and 17 ng cqll di ce lls in HEC-16 (Table ] .2). Tha t is. there was a 2o-fold
great er increase in iP1lf.rP secreti on in HEC- 16 cells compared 10 CaSh Tre atmen t wi th
1.2S-dihydro l()'VitaminD l resulted in iPTHr P secretionofO.12 and 6 ng cql ld' cells in CaS ki
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and HEC·1 6 cells. respecti vely . this corresponded to a 50-fo ld grealCt' increase in iPTHrl'
in HEC-16 cells compared to CaSIcicells. Incubation of the cells wi th dcxamcthasonc
resulted in iPTHrP levels of 0 .16 and 3 ng cq/106 cells in the CaSki and HEC-16 cells.
respecti vely . Again. iP1lIrP secretion by HEC·16 cells exceeded that of CaSlci ce lls. this
time by near ly 2o-fold. Treabnent of the cells wilh 17Ji-estradiol resulted in iPT HrP
secretion of 0.538 and 11 ng eqllo' cells for CaSki and HEC· 16 cells, respective ly. ~hich
roughly translates to a 30-fold greater secrencn in HEC· 16 cell s. Pregesteroee stimulation
res ulted in iPTHrP levels of 0.22 and 20 ng eql lW cells in CaSki and HEC· 16 cells,
respec tively, or nearly a IOO-fold greater secretion in HEC·1 6 cells.
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Figure 3.1: Dose-d epend ent effects of EGF on I"THrP mR NA
express ion. CaSki cells were plated at 2.4 x 10 ~ cells/well in 6-well cluster plates
and grown to 50% confluence . followed by a 24 hour period of serum deprivation.
CaSki cells were then exposed to DMEM alone (basal ) or in DMEM plus the
indicated concentration of EGF for 24 hours. Total cellular RNA was prepared as
described in "Materials and Methods ". Experiments were repealed in triplicate .
A) Northern bioi analysis of PTHrP mRNA expression after treating the cells with
varying concentra tions of EGF.The filters were hybridized with " Pclabelled
cyclophilin probe as a control for RNA loading.
B) The intensities of the autoradiograph signals were quantified by spot densitometry
and changes in PTHrP mRNA expression (normalized to cyclophilin) after EGF
treatment were expressed as a percentage of control cells receiving DMEM alone .
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Figu re 3.2: Dose-dependent effect s of de xamethasone on PTH rP mRNA
expressio n . CaSki cells were plated at 2.4 x 10 S cells/we ll in 6-well cluster plates and
grown to 50% confluence , followed by a 24 hour period of serum deprivat ion. CaSki ce lls
were then exposed 10DMEM (in the presence of 10% FCS; contro l) or in DMEM (in the
presence of JO%FCS) plus the indicated concentration of dexamethasone for 24 hours.
Total cellular RNA was prepared as described in "Materials and Methods ", Experiments
were repeated in triplicate .
A ) Northern blot analysis ofPTHrP mRNA expression after treating the cells with
varying concentrations of dexamethasone. The filters were hybridized with UP_labelled
cyclophilin probe as a control for RNA loading.
B ) The intens ities of the autoradiograp h signals were quantified by spot densitometry
and changes in PTHrP mRNA expression (normalized to cyclophilin) after
dexamethasone treatment were expressed as a percentage of control cells receiving
DMEM + 10% FCS. 67
A 1,25-dihydroxyvitamin D]
(M) ..:C:::t1"""'~"'''''"__'':':::''''''';:'-__
PTHrP
Cyclophilin
B 150
'"
'"~e 100
«c
z 8a:Eo 50~ ?ft.I -
f-
a. 0
en 10 .1210 .1110 .1°10 .$ 16 8 10 .7 10 .6
1,25-dihydroxyvitamin D ] (M)
Ftgure 3.3: Dose-dependent effects of 1.2S-d ihydroxyvitamin 0 30n PTHrP
mRNA expression. CaSki cells were plated at 2.4 x to' cells/well in 6-well cluster
plates and grown to 50% confluence, followed by a 24 hour period of serum deprivation.
CaSki cells were then exposed to DMEM (in the presence of to % FCS; control) or in OMEM
(in the presence of 10% FCS) plus the indicated concentration of 1,25-dihydroxyv itamin D,
for 24 hours. Total cellular RNA was prepared as described in "Materials and Methods"
Experiments were repeated in triplicate.
A ) Northern blot analysis of PTHrP mRNA expression after treating the cells with
varying concentrat ions of 1,25-dihydroxyvitamin OJ. The filters were hybridized with
.'IP-labelled cyclophilin probe as a control for RNA loading.
B ) The intensities of the autoradiograp h signals were quantified by spot densitometry
and changes in PTHrP mRNA expression (nonn aJized to cyclophilin) after
1.25-dihydroxyvitamin D, treatment were expressed as a percentage of control cells
receiving OMEM + to% FCS. 68
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Figure 3.4: Dose-d ep end ent effects of estradio l on PTHrP mRSA
exp ress ion. CaSki cell s were plated at 2.4" 10 ' cells/well in e-well cluster plates
and grown to 50% confluence . followed by a 24 hour period of serum deprivation .
CaSki cells were then exposed to DMEM alone (basal) or in D~EM plus the
indicated concentration of estradiol for 24 hours. Total cellular RNA was prepared as
described in "Materials and Methods". Experiments were repeated in triplicate.
A ) Northern blot analysis of PTHrP mRNA expression after treating the cells with
varying concentrations of estradiol. The filters were hybridized with l~P- l abe lled
cyclophilin probe as a control for RNA loading.
n ) The intensities of the autoradiograph signals were quantified by spot dens itometry
and changes in PTHrP mRNA expression (normalized to cycloph ilin) after estradiol
treatment were expressed as a percentage of control cells receiving DMEM alone.
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Figure 3.5 : Dose-dep endent effects of prog esterone on PTHrP mRNA
expression. CaSki cell s were plated at 2.4 x 10 "cells/ well in 6-well cluste r pla tes
and grown to 50% confluence , followed by a 24 hour period of serum deprivation.
CaSki cells were then exposed to DMEM alone (basal) or in DMEM plus the
ind icated concentration of proge sterone for 24 hours . Total cellular RNA was prepared
as described in "M aterials and Methods ". Experiments were repeated in triplicate.
A ) Northern blot analysis of PTHrP mRNA expression after treating the ce lls with
varying concentrations of progesterone. The filters were hybrid ized with "P clabelled
cyclophilin probe as a contro l for RNA loading .
8 ) The intensities of the autoradiograph signals were quantified by spot dens itometry
and changes in PTHrP mRNA expre ssion (normal ized to cycloph ilin) after progesteron e
treatme nt were expressed as a percentage of control cells rece iving DMEM alone.
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Figure 3.6: Time course of PTHrP mRNA expression under basal
conditions. CaSki cells were plated at 1.5 x IOl cells/we ll in 6-well cluster plates
and grown to 40% confluence , followed by a 24 hour period of serum deprivation.
CaSki cells were then exposed to DMEM alone. CaSki cells were removed at indicated
time intervals (0-72 hoursj.Total cellular RNA was prepared as described in
"Materials and Methods". Experiements were repeated in triplicate.
A ) Northern blot analysis of PTHrP mRNA express ion after treat ing the cells under
basal condit ions at indica ted time intervals . The filters were hybridized with a
" Pdabelled cyclophilin probe as a contro l for RNA loading.
B ) The intensit ies of the autoradiograp h signals were quant ified by spot densi tometry .
Changes in PTHrP mRN A expression (normalized 10cyclophilin) after basal treatme nt
were expressed as a percentage of control cells at lime zero.
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Figu re 3.7: Time cour se of FCS medi at ed effect on I"THrP mR NA
expressio n. CaSki cells were plated at 1.5 x 10 ' cells/well in 6-well cluster plates
and grown 10 40% confluence, followed by a 24 hou r period of serum deprivation.
CaSki cells were then exposed to DMEM alone or DMEM plus 10% FCS. CaSk i cells
were removed at indicated time intervals (G-72 hours).Total cellular RNA was prepa red
as described in "Materials and Methods ". Experiments were repeated in triplicate.
A) Northern bioi analysis of PTHrP mRNA expression after treating the cells with 10%
FCS at indicated lime intervals. The filters were hybridized with a " Pdabelled
cyclophilin probe a" a control for RNA loading.
B ) The intensities of the autoradiograph signals were quantified by spot densitometry.
Changes in PTHrP mRNA expression (normalized to cyclophilin) after 10% FCS
treatment were expressed as a percentage of control cells receiving DMEM alone.
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Figu re 3.8 : Time course of EGF medi ated effect on PTHrP mRNA
expression. CaSki cells were plated at 1.5 x 10 'cells/well in 6-well cluster plates
and grown to 40% confluence, followed by a 24 hour period of serum deprivation.
CaSki cells were then exposed (0 DMEM alone or DMEM plus EGF (20 ng/mL).
CaSki cells were removed at ind icated time intervals (0-72 hoursj.Total cellular RNA was
prepared as described in "Materials and Methods ". Experiments were repeated in
triplicate .
A) Northern blot analys is of PTHeP mRNA expression after treating the cells with EGF
at indicated time intervals. The filters were hybridized with a " Pclabelled
cyclophilin probe as a control for RNA loading .
B ) The intensities of the auto radiograph signals were quantified by spot densitometry.
Changes in PTHrP mRNA expression (normalized to cyclophilin) after EGF
treatment were ex.pressed as a percentage of control cells receiving DMEM alone .
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Fi gure 3.9: T ime course of dexamethason e medi at ed effect on PTHrP mRNA
ex pressio n . CaSki cells were plated at 1.5 x 10' cells/well in e-well cluster plates
and grown to 40% confluence, followed by a 24 hour period of serum deprivatio n.
CaSki cells were then exposed to DMEM alone (in the presence of 10% FCS) or in DMEM
(in the presence of 10% FCS) plus dexamethasone (IO·I M). CaSki cells were removed at
indicated time intervals (0-72 hours).Totai cellular RNA was prepared as described in
"Materials and Methods". Experiments were repeated in triplicate.
A) Northern blot analysis of PlllrP mRNA expression after treating the cells with
dexamethasone at indicated time intervals. The filters were hybridized with a "Pclabelled
cyclophilin probe as a control for RNA loading.
B) The intensities of the autoradiograph signals were quantified by spot densitometry .
Changes in PTHrP mRNA expression (normalized to cyclophilin) after dexamethasone
treatment were expressed as a percentage of control cells receiving DMEJ\1alone.
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Figure 3.10: Time course of l,2S.dihydroxy,,·itamin D 3 mediated effect on
PTHrP mRNA expression. CaSki cells were plated at 1.5 x 10 ~ cells/we ll in
6-we ll cluster plates and grown to 40% confluence, followed by a 24 hour period of serum
deprivation. CaSki cells were then exposed to DMEM (in the presenc e of 10% FCS) or
in DMEM (in the presence of FCS) plus 1,25-d ihydroxyv itam in DJ ( IO·I M) . CaS ki cells
were remove d at indicated time intervals (0-72 hours ).Tolal cellular RNA was prepared as
described in "Materials and Methods". Experiments were repeated in triplicate .
A ) Nort hern blot analy sis of PTHrP mRNA expression after treating the cells with
1,25 dihydroxyv itamin D 1 at indicated time intervals . The filters were hybridized with a
J1 P-Iabelled cyclophilin probe as a contro l for RNA loading .
B ) The intensitie s of the autoradiograph signa ls were quantified by spot densito metry .
Changes in PTHrP mRNA expression (nonn aiized to cyclophilin) after 1,25-
dihydroxyvitamin D, treatment were exp ressed as a percentage of control cells receivi ng
DMEM alone. 75
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Figure 3.11: Tim e cour se of estradiol mediated effect on PTH rP mRNA
expression. CaSki cells were plated at 1.5 x 10' cells/well in 6-we ll cluste r plates
and grown to 40% conflue nce, follow ed by a 24 hour period of serum deprivation.
CaSki cells were then exposed to DMEM alone or DMEM plus estradiol (10-' M).
CaSki cells were removed at indicated lime interval s (0-72 hou rsj.Total cellu lar RNA was
prepared as desc ribed in "Materials and Methods". Experiments were repeate d in
triplicate.
A) Northern blot analy sis of PTHrP mRNA expression after treating the cells with
estradiol at indicated time intervals . The fillers were hybridized with a II P-labelled
cyclophilin probe as a contro l for RNA loading.
B) The intensities of the autoradiograph signals were quantified by spot densitometry.
Chan ges in PTHrP mRNA expression {normalized to cyclo philin) after estrad iol
treatment were expressed as a perce ntage of control cells recei ving DMEM alone .
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Figure 3.12: Time course of proge sterone mediated effect on PTHrP mRNA
expression. CaS ki ce lls were plated at 1.5 x 10 l cel ls/well in 6-well clus ter pla tes
and grown to 40% confluence , followed by a 24 hour period of serum deprivat ion.
CaSki ce lls were then exposed to DMEM alone or DMEM plus progeste rone ( 10' M).
CaSk i cells were removed at indicated time intervals (0-72 hours).Total cellular RNA was
prepared as desc ribed in "Materials and Methods ". Experiments were repeated in
triplicate.
A) Northern blot analys is of PTH rP mRNA express ion after treating the ce lls with
progesterone at indicated time intervals . The filters were hybridized with a " Pd abelled
cyclop hilin probe as a control for RNA loading.
B) The intensities of the auto radiograph signals were quantified by spot densitometry.
Changes in PTHrP mRNA express ion (normalized to cyclo philin ) after progesterone
treatment were expressed as a perce ntage o~fontrol cells receiving DMEM alone .
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Fi gu re 3.13: C hanges In Immunoreactive (I) PTH rP levets In respon se to
va ry ing doses of EGF . After 24 hour period of growth factor depri vation (basal ),
CaS ki ce lls at SO% confluence were treated w ith DMEM alone (basal) or with DMEM plus
the indicated co nce ntra tion of EGF foe 24 hou rs. Cond itioned medium was removed at 24
hours and was assa yed (oc iPTHrP as described in -Materials and Melhods~.
Resu lts are corrected (01"ce u number and are representative of replicate (at k.asr.lriplicale)
expe riments . Eac h bar represe nts the mean ± SEM of rep lkal:e determinations expressed as
ng eq of hPTHrP(1.34 )1 10· ce lls. · s ign ific an t d ifference from control (S tude nt's t- test,
p<O.OI)
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Figure 3.14: Cba nan In lmmunorea ctln (I) PTHrP levels in re spon se 10
vB['yin g do ses or dex ame thason e. After 24 hour period o f growth factor deprivation.
CaS ki ce lls a t SO%confl uence were treated with dexame thasone (in the prese nce of 10%
FCS ; conltO l) 01" w ith DMEM (in me presence: o f 10% FCS ) plus the indic ated ccecencauoe
of dcumethasone for 24 Ixlun . Condi tioned medi um was removed at 24 hours and was
assayed for iPTHrP as descri bed in ~Maleria1s and MClhods~ .
Results are corrected roc ce ll number and are represe ntative of replicate (at least triplicate )
experime nts. Each bar represe nts the mean ± SEM of replicate dete nninations expressed
as ng eq of hP'THrP<I . 34 )1IO "cc lls. · signiflCant difference fro m control (S rudenl' s r-tesr.
p<O.OI)
79
co 0 .25
..
...
0 .2
-::
ii: 0 .15
X
I- 0.111.
<T
.. 0 .0 5
Dl
c
ce 10 .12 10 .11 10-10 10-1 10-1 10.7 10-ll
l ,2S·dlhydroxyv llam ln D, (M)
Figure 3.15: ChaRles In Im m unoreacllve (I ) PTHrP le vels in respo nse 10
varying d oses or 1.25-dlhydroxyvitamin OJ ' After 24 hour period of growth
factor deprivation. CaSki cells at SO% confluence wen: nea red wilh DMEM ( in the
presenc e of 10'i>FCS; control) or with DMEM (in the presence of 10% FCS ) plus
the indi cated concenrrar.ion of l.25-dihydrox)'Yiwnin D, for 24 . Conditioned medi um
was remo ved at 24 hours and was assa yed for iPTHrP as described in HMalerio1ls and
M eth ods H •
Resul ts are corrcctcd for cell number and arc representati \'Cof replicate (at kasl: ui pl icale )
experi me nts. Each bar represe nts the mean ±SEM o f replicate de lenninations expressed
as ng eq o(hPTItrP( I-34 )1IO ·cc lls . · signifi cant differe nce from contro l (Student's
t-rest, p<O.Ol)
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Figure 3.16: C ha ng" In Immunon ac:tin (I) PTHrP levels in res ponse 10
varying doses or 178-rsl radiol. After 24 hour peri od of growth (actor deprivation.
CaSk.ice lls al SO%co nfluence were treated with DMEM alone (basal) or with DME.\.1 plus
the indicated ccocentr erloe of 176-estradiol for 24 houR. Co nd itioned medi um was
re moved.at 24 hours and was assayed for iP'THrP as described in ~Materials and
Methods~ .
Results are cooecec for ce ll number and are represe ntauve of replicate (at leasttriplkate)
experiments. Each bat represe nts the:± SEM of replicate detenninations expressed as ng eq
o f hPTHrp( I. 34V 10 °ce lls. · significant difference from contro l (Stude nt' s t-test, p<O.OI)
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Figure 3.17: Ch anges In immunore a cti ve (i) PTDrP levels In response to
vary ing doses or progesterone . After 24 ho ur period of growth factor depri vation.
CaSki cells ar 50% confluence were treated wim DMEM alone (basal ) or with DMEM
plus me indicared concentratio n of progesterone for 24 hours. Conditioned medi um was
removed al 24 hours and was assayed for iPTHrP as described in "Materials and
Methods".
Results are corrected for cell number and are represenrauve of replicate (at least triplicate)
experiments. Each bar repre sents the ± SEM of replicate detenninations expressed as
ng eq of hPTHrP( (. )4 )1 10 "cells. *significant differenc e from control (Stude nt's t-test,
p<O.OI)
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Figure 3.18 : Time course or ImmunorucUve (I) PTHrP un de r basal
co nd il io n s . Af te r 24 hours of serum free ccodiuces, fresh medium (DMEM alone)
was added to the:cells. Conditioned medium was removed at timed inlef'Vals and was
as~yed for iPTHrP as descri bed in MMate rial s~ Methods M •
Results arc corrected for cell number and arc represe ntative of replicate (at least triplicate )
experime nts . Each bar represen ts the mean ± SEM of replicate determinations expressed
as ng eq of hPTHr P(I·34V 10' ce lls. · s igni ficant d ifference from contro l (S tuden t 's
t-test, p<O.OI).
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Figure 3.19 : Time cou rse or Immunorea ctive (I) PTHrP in re spons e
to 10 % FCS . After 24 hours of serum free conditions. fres h. medi um (DMEM +
10% FCS ) was added to the ce lls. Conditioned medium was removed at timed
interval s and was assa yed for iPllfrP as desc ribed in "Materia ls and Methods ".
Results are corrected for ce ll number and are representative of replica te (at least
tripli cate) experiments. Each.bar represe nts the mean ± SEM o f replicate
determinations expressed as ng eq ofhPTHrP(I ·34 )/ to 'cells. "sign jficanr
d ifference from control (Student's t-test . p<O.OI) .
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fig ure 3.20: Ti me course or Immuno~.dh'e (i) PTHrP in res ponse
10 EGF. After 24 hours o(scJUm frcecondition s, fresh medium(DMEM alone )
plus EG F flO nglmL) was added to the cells. Conditioned medium was removed
at timed interval s and was assayed COl"iPTHrP as desc ribed in "Mate rials and
Methods",
Resul ts arc corrected for ce ll number and are repeeseraanve of rcpOCalC(at least
trip licate ) expenmems. Each bar l'C'presents the mean ± SEM of replicate
dctcnninations expressed as ng eq of hP11lrP( l-34)1 Iff ce lls. "signi ficant
difference from control (Student's t-rest, p<O.OI).
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Figure 3.1:1: Ti me course or lmmune reacn ve (I) PT HrP In r es po RSC' 10
dexamet ba.wne. After 24 hours of serum free cond itions. fresh medium (DMEM +
10'% FCS) plus dexamethasone ( 10 " M) was added to the cells. Conditioned mediu m
was removed at rimed intervals and was assayed far iP11irP as descri bed in ~Material5
and Methods · .
Results are corrected (or cell number and are represe ntative ofreplicaJ:e (at least tri plic.uc)
ex peri ments. Each bar represen ts the mean ± SEM of replicat e:del:erminations expre ssed
as ng eq of hPTHrP( I· 34)1 10 · cc lls. · signiflCantdiffe rence: from contro l (SlUdenf s
1-le St.paJ.OJ) .
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Flgur~ 3.2 2 : Ti me course or Im m unor eac:U"e (I) PTHrP In re spo nse
to t .25-dibyd ro xy" ltamin DJ • After 24 hours of serum free conditions. fresh
medium (DMEM + J()'I, FCS) plus l,.2S-dihydroxyvitamin D, (10 -oM) was added
to the ceus. Conditioned medium was removed at timed intervals and was assayed
fo r iP'IHr P as desc ribed in ~Maleri als and Methods N •
Results are co rrected foe ceu number and are rep resen tative of replicate (a t least
uiplicate) experiments. Each bar represents the mean ± SEM of replicate
dctenninations expressed as ns eq of hPTHrP(I ·34)/ 10· cells. · signiflCant
d ifference fro m control (Sludc nt' s t-rest, p<O.OI ).
87
.!!
a:; 0 .75
u
.~
ii: 0 .5
:i:
:;:
go 0 .25
'"c
o 24
Time (h)
48 72
f igur e 3.23 : T ime co urse or immunoreactive (I) PTHrP In response
to 17B-estradlol . Afte r 24 houn of serum free conditions. fresh medium (DMEM
alone) plus 178-estradiol ( 10" M) was added (0 lhe cells. Cond itioned medium was
removed at timed intervals and was assayed fIX iPTHrP as descri bed in ~Materials
and Melhods M _
Results are correc ted fIXcell number and are represe nlatiYeof replic.r e (at least
triplicate) experiments. Each bar represents lhc:mean :t:: SEM of replicate
oererrranauons expressed as ng eq of hP'lHrp(I -34)f 10"cells. · signiflCant
difference from control (Student's t-test, p<O.OI).
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Figu re 3.24: T ime (:ou rse of Im m uDo reac:lln (I) PTHrP In r espo nse
to proKeslerooe. After 24 bouts of se rum free conditions. fresh mediwn (DMEM
alone ) plus progesterone ( 10" M) was added (0 me cells . Conditioned medi um was
removed at timed interv als and was assayed for iPTIlrP as descri bed in "Marenals
and Method s".
Results are corrected for ce ll numbe r and are represe ntative of replicate (a t least
tri plica le) e:t pc:riments . Each bar represen ts the mean :tSEM of n:pl ica te
detenninations expressed as ng eq of hPTHrPCI-34)1 IO"ce lls. eMgni flCan l
d ifference from co ntro l (Srudent"s I-teSt. p<O.OI) .
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Ta MeJ. t : Effects ofEGF, dexamethasone, 1,.25-dihydro l()'Viwnin OJ. 17J,\-estradiol and
progesterone on PTHr P mRN A expression in HEC·1 6 and CaS ki cells at 24 hour s.
After 24 hours of growth factordcprivationandscrum free ccrditions.fresh mcd ium (K GM :
HEC· 16 cells; DM EM : CaSki ceUs) p lus the specified conce ntra tions of the
bormo neszfectorsindicated wereadded to the cells. Cells were removed at ti med intervals (O-
72 hour s). Tow cellular RNA was prepar ed as desc ribed in "Materials and Me thods ".
PTIl rP mRNA was anal yzed by Northe rn b lot anal ys is. The filters were hybridized with
a J~P.labc:lled cycjcphilin probe as a control for RNA loading. The intensities of the
autoradiogra phwere quantified by spot densitometry . Changes in PTIlrP m RN A expression
a fter trea tment with the spe cified hormon es/factors were normalize d to con tro l cells ~eiving
medium alone . Twenty-four hour time period results w ere taken from both the HEC· 16 and
CaSki cells and compared. • expressed as % ofContro l
Treatrnen t (dosage) HEC· 16 mRNA CaSkimRNA
exere ssicn exoresslcn
EGF (20 nl.l'/mL) 288 4'.
Dexamethasone {IO" 100 43
1.25-Dihydroxyvitam in OJ 48 45
(I0"' M)
1 7~Estradio l ( 10-' M) 164 300
Progesterone ( 10'" M) 33J 92
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T.lb~ 3.2: Effects of EGF. dexamethasone. 1.25-dihydroxyvi tam in OJ, 17jl-estradiol and
progesterone on iPTIlrP secretion in HEC- 16 and CaSh ce lls at 24 hours .
After 24 hours of growth factordepnvation and serum frecconditions.freshmedium (KGM:
HEC-16 ce lls; DMEM : CaSki ce lls) plus the specified co nce ntrations of the
hormones/fac tors indicat ed were added to the ce lls. Conditioned mcdi wn was removed at
timed interv als and was assayed for iPTH rP as described in "Mate rials and Method s".
Twen ty-fo ur hour time period results were taken from both the HEC- 16 and CaSki cd ls and
compared .
Results arc co rrec ted for cell number and an: represe ntauve o f three se para te experiments.
Each bar represe nts the mean ± SE M o f triplic ate detenni nations expresse d as ng eq of
hPTHrP( I_34 )1106 cell s.
Treatment (d osage) HEC -16 CaS ki
iPTHr P secretion iPTHrP sec ret ion
± SEM ± SEM
(nil caf l(f cells (nil caf Hf ce lls)
EGF (20 ngfmL ) 17 ± 1.5 0.86 ± O.OJ
Dexamethasone ( I0'" M) J± O.J 0.16± O.OJ
1.2S-dihydro xyvi tam in OJ 6 ± O.4 0. 12 ± O.O2
(lO ·· M)
17l}-estra dio l (10 -1M) 17 ±1.4 0.54 ± 0.04
Progesterone (1 0·' M) 20 ± 2 0.22 ±D.03
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C HA PT E R 4: DISC USSIOS
.... SE RU l\t
Feta l cal f serum contains man y compon ents including prote ins (such as hemoglobin and
bilirubin), ions (suc h as sodiwn, potass ium , chloride. calc ium and pho spha te) and hormones
(including estrad iol, progestero ne , testos terone, insulin and growth horrno ne)(Appendill A ).
Serum is a positive regulator ""iUch rapidl y enhances PTIlrP mRNA expression and
concomitantly increase s PTHr P sec retio n in cull1red normal human kerati eocytes (Kremer
Re t at, 199 1). Stud ies in nonnal hwn an kaatinocytes have sho wn lhal ind uction of PTHrP
gene expression by serum is contro lled by elements lying 1.2 kb 5' to the cap site (Kremer
R et ai, 199 1). Cis-acting eleme nts which an: responsive to serum an: known as serum
response d emen ts (SREs ). The SRE is a well -charact erized 22·nucleotide region o f dyad
symm etry that confers serum ind ucibility onto the c-fcs gene (Treisman R. 1990 ).
Compara tive sequenccanalysis an d promot er function stud ies ha ve shown that several othe r
imme dia te-c:ar ly genes. includ ing zif26 8 and egr- I, contain fcs -like SRE s in their S' flankin g
sequences and requ ire these SREs for induction in response to serum (C hri sty Band Na thans
D. 1989; Qureshi SA et al , 1991). HOwevCT, the e-ros gene doe s not stand as a proto type
for all inun ediatc:-earlyresponse genes which an: induced by SCTWTl. Forexample, no foe-like
regula tory elements have been found within several lcilobases or the 5' or ) ' flanking
sequence s or within the c:odingseq uenc es of the JE gene, but the JE gene is indoccdb y serum
(Freter RR et al, 1992).
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My experiments have demo nseared that in CaSk i cells, serum induction of Pll-IrP mRNA
expression was rapid. with an inaeasedetectable within 30 minutes and nwtimaJ at 2 houn.
At 2 bours, there was a 1.5·fo ld increase in Pll-IrP mRNA com pared 10 zero time po int .
The lim ing of the' response was simi lar 10effects obse rved in GH..C, pituitary ce lls (Holt
EH et at, 1994). Serum rapidl yenhanccd PTHrP mRNA expn:ss ion and subsequently also
increased PTHrP secretion.
The presence c f els-acting regions n:sponsiv e lo growth fac tors and serum within the PT fJrP
promote r region using transie m transfection in normal human kerarinocytes in cultu re has
previously been reported (Kremer R et al, 1991). These studies have shown that se rum
induction of tile PTHrP gene was controlled by SREs. Despite this. sequencin g of 950 bp
upstream of the cap site did not reveal a consensus sequence for an SRE of the e-ros typ e
(Karapli s A et al; 1990). Thi s indica tesei ther that lhe SRE is different from that of the c-fo s
gene or. alternatively . that it lies furthe r upstream ofthe cap site.
4.2EGF
Epidermal growth factor (EG F) is a mitogen which stimulates the growth of man y
mesenchy mal and epithe lial celllmes in culture (Carpenter G and Cohen S. 1979; Carpe nter
G. 1987) . EGF induces a pleiotyp ic response, characterized by Increases in the transpo rt
of low molecular weight compounds . glycolytic activity , nucleic acid and protein synt he si s,
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and phospho rylatio n of membrane -assoc iated and intr.lCeliular proteins (Carpen ter G and
Cohen S, 1979; Fox CF etd, 1982; Sarup JC a ot, 1988). Amon g the many gro wth factors
tha t have been repo rted. EGF is one of the po lypept ides implicated in the growth o f
malignant cells (t.eue RJ et ei, 1993).
It has been reporte d tha t EGF is presen t in many tissues and plays an import an t role not
on ly through its funct ion as a potent mitogen in a variety of ce lls, but also as a regulator or
modulator of horm one sec retion in some endoc rine tissues (Taga M et al, 199 5). In
oncogenesis. the gro wth reguIaIing nerwork of EGF and ether growth factors may be
involved in neoplastic ce llular proliferation (Lelle RJ et 01. 1993).
'Themembran e recept or for EGF is a well-characterized 170 kDa glycoprotein (Co hen SJ,
1982). EGF receptor (EGF R) bas an extcma.ldomain as the EGFbinding regjon. an internal
d omain containinga tyros ine-specilic kinasc and a transmembranedomain( Cohe:n 51. 1982).
When EGF binds to its receptor. it acti vates protein kinase , which phospho rylates vario us
ce llular proteins, as well as EGFR itsclf (A lsat E el al , 1993). Autophosphory lat ion o f
EGF R is necessary in orde r to mediate the physiological actions of EGF and re flects the
prese nce of biological ly acti ve receptors in the ce ll (A1sat E el 01, 1993).
Cervi cal, ovarian and endometrial cancer have been found to exhibit strong EGFR expr ession
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{Battaglia F et ai , 1989 ; Bauknec ht T t!l aI. 1989) . These findings su ppo n tbe idea that the
enhanced ex pressi on of EGFR stimul a tes the pro liferative capacity of tum ours . whic h is
clinical ly visible by its more aggressiv e behaviour (Ba uknec ht T et al , 1989 ). Th e rate of
transc riptio n o f the EG FR gene is regulated by EG F itsel f. leading to an inc rease in EGF R
mRNA (Earp HS et ai, 1988 ), as well as by other facto rs and horm ones suc h as PTH and
PT HrP (Alsa t E et al , 1993). Thus, EGF may pia) ' an importan t role in the growth
promotion of these neo plastic cells (Le lle RJ et al. 1993).
In CaSki cell s. we ha ve demonsuated an increasein PT HrP expression and secretion wi th
EGF treatment. In dose-response and time course experi ments. there was a maximal4.5· fold
increase in PTH rP mRNA expressionat 20 ng/mL at 24 hows. The time co urse experiments
also revealed that the max imal 4.5· fold increase in PTHrP mRNA express ion was achieved
at 2 hours and maintained thi s levelof prod uction for up to 24 hour s, compared to zero time
po int. There was a sim ilar increase in iPTHrP secretion \,\,lth a 4-fold increase in iPT HrP
secretion at 24 ho ucs. Th is is presuma bly a direc t res ult from the increase in PllfrP mRN A
expressio n.
The results from my expe riments are similar to those of otber investigators . EG F has bee n
repon ed to cause an increase in PTHr P in a vari e ty of d ifferent cells includ ing a canine
squamous carc inoma cell line (Grone A et al, 199 8), in human prostatic epithe lial cells
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(C ramer SO et al, 1996) and in hwnan kera tin ocytes (Allinson. ET el al . 1992). EGF also
produced a signifi cant increase in PTH rP produ ction in HEC· 16 cells (Rahi mrula M and
Kaiser SM. submitted) and in gynec ic squamous carcinoma cells (Tait OL et al, 1994 ).
Hence. CaSki cells liie many olher cells demonstrate an observable increase in PTHrP
prod uction in response to EGF .
It has been sug gested mat me mechanism whereby EOF regulates PT HrP expression is
mediated via an interaction of the pe ptide with EOFR. It is also known tha i CaSIcicells
ove rexpress EGFR (Singer GA et al , 199 8). Thi s could eccoun r for the su bstan tial increase
in PTHrP in response to EOF. Th ai is, the EOF ligand may work via EG FR to increase
PTH rP levels . I cannot finn ly conclude howe ver, that EOF regularesthe ra re of PTHrP gene
transcripti on , since mRNA level s ma y be enhanced by othe r process. That is . the re could
be an increase in gene translation M mRNA stability. This could be determined by
perfo rming nuclear runoff assays or cycloheximide treatme nt. respectively, on lIle cells. In
one study, EGF treatment of human kera nnocytes increased IraJlscriptional activi ty of the
P2 promoter of the PTHrP gene , sugges ting the presence of [OF res ponse cle ments in that
region of the promoter (fteath JK et al. 199 5). Th is has nOI been confirmed since EOF
res ponse elem ents have Dot bee n found in the PT HrP gene to date .
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4..3STEROID HOR.'\tO NES
Steroid horm ones arc synthes ized from choleste rol and interact with the steroid/nuclear
receptor superfamily which shan: common functional domains (Evans RM. 1988;
Mangelsdorf OJ et a l, 1995). These domain s are responsible for propen ies such as ligand
binding. d imerization. DNA binding and uansactivation (Glass CtC. t 9(4). Ligand binding
is typ ically followed by dimerization v.i th subsequent bindingof the Iigand· receptorcomplex
to specificDNA sequences possessing a high level of dyad symmetry. Such binding sites
are termed "hoemc oe-respoese eleme nts " (HR.E.5) (Bea IO M. 1989 ) and contain perfect or
imperfect palindromic ordirectly repeating half-sites that are nonnaIly five to six nucleotides
in length. It is through thesesequences that stero id hormone receptors exert their regulatory
effects on speci fic genes (Freedman LP and Luisi BF. 1993).
4..3.1 D~umdb.son~ . nd t .1S-0ihydro~il.D1i. 0 .):
Dexamethaso ne and 1.25-dihydroxyvitamin OJ are steroid hormones and have been shown
to modulate PTHrP gene expression in normal (Kremer R et al, 199 1) as wel l as malignanl
(Ikeda KC et at.1989) cells.
The act ive fonn of vitamin D. 1.25-dihydro "Y"'iwnin. OJ. functio ns via inleraction with a
nuclear recepto rf vuami n D receptor [VORl) in a manneranalogous to other members of the
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ste roid-thyroid hormone superfamily (DeLuca HF et al, 199 8). Vitamin D receptors are
widely distributed (lan NC et 01. 1984 ; Reichel H el ol . 1989).
Vitamin 0 respo nse d emen ts (VDREs) are small segments of DNA that represent the
binding domain for the vitam in 0 receptor. These d ements med iate the responsi veness of
a gene to 1.25-dihydroX}"'-itaminO) and result in IJ'atISCriprionaI activat ion or repres sion of
that gene. The VORE cons ists o f a d irect repeat of two hexanucleoride half- sn es separated
by a three-nuc leotide spacer (Ozono K et al, 199 1). The first exam ple of a negative VORE
(nVORE) was identified in the promo ter region of the human PTH gene and med iates the
suppression of the PTH gene by 1.15-d ihydro:q'Vitamin OJ (De may MB et al, 1992).
Ho.....ever. it differs from a classical VORE in that it has only one motif (Demay MB el at,
1992); the d ement co ntains only one o f the two bexame ric DNA sequences that forms the
ca n: sequence of the consensus DNA sequence (YORE ). II has been suggested that the
VORE sequence and the presence of either one or two hexameric sequence moufs may play
a role in detennin ing whether there:is an increase or decrease in transcri ptional activity of the
individual gene (Darwi sh H and DeLuca HF. 1993) .
The prese nt stud ies have indicaled thai I.2S-dihydroxyvitalTlin OJ produced a down-
regulation of PTH rP mRN A expression in both a dose - and time-dependent manne r. At 24
hou rs , prnrP mRNA levels had fallen to 500/0of zero time poin t level. However. there:was
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an initial increasem mRNAat 4 hours . Similarly, a decrease iPTH rP secre tion was observed .
Down-re gulano nof PTH rP mRN A expressio n and iPTHrP secretion coul d be explained by
the pre5l:1ce of a nYO RE. The PTHrP gene containsaDNA 5equence which is homol ogous
to the nVORE o f hwnan PTH (Ni sh.ishila T et 01.1991). Kremer R et 01 (1996a) have
localized this nYORE to a region between -12 and -0.3 kb upstream of the transcriptional
stan site. Th is evidence SO'Ongly suggests that the nYO RE resu lts in inhibitio n of PT HrP
ex pression and secretion in CaS ki cells. Themec hanism whereby 1,25-dihydro xyv itam inD J
weakens the bindin g betwee n the nYORE and VDR, which results in a decrease in
transcriptional and conse quently trans lational acti v ity of a gene. is unclear and is the subject
o f current inve stigatio n.
Darwish and DeLuca( I999 ) have recently reported a putative transc ription fact or that bind s
10a site adjacent to the nYORE in the promoter rq;ion of the hPTH gene . Transfec tion
experiments have determined that this factor is required for the high transcriptional acaiviry
of the hPTH gene . This high activity is significan tly suppressed by I,2S-dihydro xyvitamin
OJ. This facto r seem s to be expressed in several cell ty pes and may be expressed in the
CaSk i ce lls. It is possi ble thai this transcripti on fac tor. Of an equ ivale nt factor thai act s in
a manner simi lar to it, may explain the mechanism by which PTH rP is suppres se d in the
presence of 1,25-d ihydroxyvi tamin OJ.
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It has also been suggested thcparent substra te lalS-(OHh D:!. may prod uce a majOf stable
metabol ite callcd 1alS-<OHh-3-epi-D:!. This has been found to suppres s PTH secretion by
50% in cultured bovine parathyroid cells (Brown AJ et ai, 1999 ). Th is metabo lite may
contribute to the prolon ged suppressive effec t of lal5-(OHh Dj on PTH gene transc ription.
This may also help explain the suppressive effect of I a25 -(OHhD ) on PTHrP gene
expression
4.3.1.2 Du.• mella.soDe:
Dexamethasone is a synthc1:ic glucocorticoid. commonl y referred to as a gluoocorticoid
agonist. It is tho ught to function in a manner similar to 1.25-<1ihydroxyvitamin Dj and other
members of the steroid-thyroid hormone superfam ily (BeaIO M. 1989). Like vitamin D
receptors, glucoco nico id receptors are widel y distributed (Lan NC et 01. 1984; Reichel H et
ai , 1989 ). Functio nal receptors have been dem onstrated in human uterus (Giannopoulos G
etal , 1983).
In our studi es, dexamethasone produced a bi phasic response . A dose - and rime-depeodenr
decre ase in PTH rP mRNA expression was observed with a maximaJ.decrcase of50% of time
zero level at 24 hours . However, there was an increase in PTHrP mRN A expres sion at I
hour which pers isted to 6 hours after trea tme nt. Similarly, a 500/0decrease in iPTHrP
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secre tion was observed at 24 hours . Glucoc oltic oids have prev ious ly been reponed to
profoun dly do wn-regu late PTIlr P expression (l u C tl at, 1989; Glatz JA et ai, 1994) and
results of the current studies support these findi ngs.
Therefore, dexamdha.sonehas been estab lished as a negative regularor of PTHrP in the
cervical squamous can:inomacelli inc. CaS ki, with effects that arc dose-depcndcnt and rapid.
The action of dexam ethasone was shown to be steroid-specific as exposure of the cells to
17~stradiol, fOC" examp le. caused an increase in both PTIlrP expression and secretion. It
is possible that the effects of dexamethasone are mediated via classical receptor response
clem ents in the S' regulatory region of the PTHrP gene. G1ucocolticoi d response elements
(GREs) , like the VRD Es, are small segments of DNA that represent the binding domain for
the glucocorticoid honnones. The GRE has been proposed to be a IS-mer consensus
sequence ( Bea to M, 1989). II is an ticipat ed that one or more: so-called negalive
glucoco mcoid respon se elements (oG REs) will be found in the S' flanking regionof the
PTHrP gene. nGREs are less ....ell de fined than positive O REs (Beato M, 1989). S...:h
elements have not been found in the 2 kb of DNA S' of the putative up-stream promoter of
the PTHr P gene or by transfectiOll tec hniques (Lu C el oJ, 1989). It is possible that the
consensus sequence for a nGRE is very different from the typical ORE sequence or it may
be located fwthe r S' or 3' to the rq;ion of the PTHrP gene examined. Tberefcee , the
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mechanism by whic h dexamc1hasonc decreases PTIhP mRNA expression is unkno \l,u and
is the subjec t of current in,,·estigation.
In summary. both 1.25-dih ydro xyvitaminDJ and de xamethasoneprod uced a down -regula tion
of PT Hr P mRNA express ion and iPT HrP secretion. This is similar to results seen in other
investigation s. G latzlA et a / ( 1994) found that dexamcthasonedecrused prnrP express ion
in a squamous cancer cell line. Dvir R et al ( 1995) found tha t PTHrP decreased PT HrP
secret ion by 15% in amn iotic fJuid cells. Nishis hita T et al (1 99 8 ) and Falzon M and Zo ng
J ( 199 8) found tha t 1.25-d ihydroxyvltanUn OJ dec reased gene express ion o f PTHrP . M y
resul ts confi rm that dexamethasone and 1.25-di hydro xyv itamin OJ have an effect on CaSki
cells and down -regulat e PTHrP express io n and secre tion . Since it is kno wn that both
dexamethasone and l .2S-dihydroxyvitamin OJ can down- regulate PTHr P and that PTH rP
is invo lved in emcc rinezparacrine functions then it may be poss ibl e to use this information
to alte r the growth of cenain cells using these ste roid honno nes with respect to the e ffect
the y have on PTI-lrP production. Further wo rk must be completed in the are a in order to
determine ho w PTHtP affects the gro wth of a particular ce ll type.
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4.3.1 Su slero ids: PrOlcsluone aad 1 7~Eslndiol :
The sequence elements recognized by different steroi d receptors constitute a fami ly of
identical or closely related seq uences. As previous ly mentioned, the co nse nsusGRE is a IS
bp palindromic sequence (Bea to M. 1989). This sequence cannot be:disc riminated from the
proge stero ne respo nse element (PRE ) sequence. The ques tio n o f how glococorticoid and
progesterone receptors can generate distinct panerns of gene: expression despite simi lar. if
not identical DNA sequence recogni tion properties is a central question in steroid hormone
biology .
The minimal functional estrogen respo nse element (ERE) consen sus sequence is a 13 b p
perfec t pal indrome . The half- site of the ERE is identical 10 the half-site of the thyroid
honn one response eleme nt (fRE) (G lass CK et aI. 1988). It. 100. shares a few essen tial
nudeotidcs with the GRE (Beato M, 1989 ). No evidence exists tha t the ERE palindromecan
inte ract with steroid horm one:rec eptors other than the ER. However , a few single mutations
with in the ERE are suffic ient en ough to co nvert il to a GRE (Kloc k G et al, 1987). This
suggests tha i there are onl y mi nor differenc es in the DNA recogni tion mechanisms of the
various ho rmone receptors.
Human progesterone receptors are expres sed as two majo r isofonn s: PRA and PRB . PRA
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and PRB arc products ofa singie geDe. butcach tran script is individ uallyrqu.lated by unique
promoter seque nces upstream from two di fferent transc riptional start sites (Kastner P~, oJ.
1990) . It has become qui te clear that PRA and PRB are not functionall y identical. PRB is
a stro ng transCriptional activato r on many more PRE containing promoters than PRA (Wen
DX et of. 1994). These differences arc cell-specific but a few exceptions do ex ist w he reby
the transcript ional acti vity o f PRA can be signi ficantly great er than that of PRB (Tora L et
01.1993).
like progesterone,rece ptors fo r 17fkstradiolarc expeessedas two major isofonns: ERa and
ERP. ERP also has several.mRNA variants including ERP 1 and ERP2 (Peterson ON et of.
1998). ligand binding inducesa conforma tional change in ER and. subseq uent DNA binding
to specific EREs present in targ et genes (Ogawa Set af, 1998). ERa and ERl} are
homologous and have a similar affini ty for 17!H:stradio l( Ku iper GG et of , 199 7). The ONA
binding domain (ORO) ofERP is highly homol ogous with tha t of ERa. imp lying tha t both
ERa and ERP sban: the same DNA responseelemenl(OgawaSetoJ, 1998). However. there
is on ly a SS% amino acid ide ntity in the ligand-btnding domain of the two isoforms
(Mosse lman Set ai, 1996). Known ligands. including estro gen meta bolit es and parti al
ago nistsl antagonists such as tarnoxifen, do not discriminate betwee n ERa and ERp (Kuiper
GG et al, 1997). Tamox ifen is a nonsteroi dal annestrogen which acts predominantl y as an
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estrogen agonist rather than as an antagonist (Macinga 0 Itt oJ. I99S). It may act as an
agonist in the prese nce ofEREs in the promo ter rcgion of he target gene. It ma y activate the
ER differen tly than if it were activated for exam ple. by17~iol. ERa and ERP each
have distinct, yet over lapping patterns of ex pres sion (K uiper GG It t oJ. 1997). The
physiological ro les of ERa and ERIJ are curre ntly under investigat ion and this will
undou bted ly increase our understanding of the mechanisms of action of mcdicaJl y and
environmentally impo rtant estrogen- like compotmds.
In my experimen ts with caSk.icel ls, a significantdose-dcpmdcnl change in PTHrP mRNA
levels in response to progesteroneceatment was not observed within me range o f doses used
at 24 hours . Time course experiments were carried out with progeste ro ne using a
concentration of 10" M which is the concentration that had produced maximal respo nses
both in our cervical sys tem and in other cell types. There was a time-depe ndent increase in
PTHrP mRN A in response to progesterone. Rapid induct ion ofPTHr? mRNA occurred in
response to progesterone wi th a ma.'(imal2 -fo ld increase observed at I hour . At 4 hours.
PTHrP mRN A began to decline and had fal len to basal leve ls (time zero ) by 24 hours. Th is
could explain the lack o f response at 24 hours in the initial mRNA dose res pon se
experiments. Tba t is, PTHr P mRNA expressi on had increased earlier and su bseq uently
returned to basal levels at 24 hours when the cell s were harvested and RNA extracted in the
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dose-re sponse studies. There was a dcse-cependenneceease in PTHr P mRNA in response
10 1713-estradiol as wel l as a timc-dependent increase in PTHrP mRNA expression. Rapid
induction ofPTHr P mRNA occurred in response to l7\l-estradiol , with a maximaJ. response
of a-fold al 6 hours . P1l!r P mRNA began to dec line by 24 hours and con linued to decrease
after both progesterone and 17~adiol stimu lation. At 48 hours the cells had reached
confluence. At this time there was a significant decrease in PTHrP mRNA expression. This
decrease in PTH rP mRNA at cellular conflu ence is observed in many monolayer cell lines
(Merryman Jl et ai , 1993; Werkmeister JR et ai, 1998).
The liming of the response 10 17j3-estradi ol is similar to obse rvations in ral uterus jfl vivo
(Thiede MA et al, 199 I) and in Gf-4CI rat pitu itary cells (Holl EH et al , 1994). The CaSki
cell line was o riginally isolated and esta blished in continuous culture in 1977. Hence. these
cells are being examined at a very high passage number. It has been noted in other nonnaJ. and
established cell lines lhal PTIlrP express ion and secretion decreased in high passage relative
to low passage numbe r cells (Kremer R et aJ, 19%b). Henderson J et at (1991) also found
tha t in respon se to serum stimulalion in both established (HPK IA) andmalignant (HPK IA.
ras) cells, dose-depe:ndent increases were grealer in HPKI A than in HPKI A·ras . The
mechanism wxlerl ying these decreased leve ls o f PTHrP expression and secretion upon
repeated cell passag e is unknown but could be a consequence of autocrine or inuacrine
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growth contro l mechanisms ofnon· or lowcrllesscr PTHrP -producing ceUs having a selective
growth advantage over-higherPTHrP-producingcells. Thi s may cxpIan why these malignan l
cells prod uce less PllirP than HEC·16 immortal ized cells.
It is not kno wn whctherthe effects of cstrog enon PTHrP mRNA in CaSkicdlsare mediated
by increased gene transcriptionor increasNmRNA stab ility . However , Ho lt EH et a/( I994 )
treated GH~C I rat pitui tary ce lls with estrog en and found that there was an increase in
PTH rP mRNA expression. They the n performed nuclear runoff transc ript ional assays 10
determine if the increase in express ion was dueto an increase in transc riptio n. The y found
a transcriptiona l response thai was rapid and transien t, peaking at the ear liest lime point
examin ed. Thi s conflfmcd that the increase in PTHrP mRN A expression was indeed due 10
an incr ease in transcript ion Although the mechanism haoi not yet been elucida ted for Cas ki
ce lls it is quite possible tha t CaSlci ce lls responded10estrog en . as did the Gl t.C I cell s. with
an increase in transc ription . It is unclcarwhelher 17~iol regulates PTI-lrP prod uction
directly or indi rectly . In one study . it was suggested thai estradsol might modula te the
nuclear nV DR indim::tly by irKreas ing circulating co ncentra tions o f I ,2S-dihydro xyvitamin
OJ (Duncan WE el al. 1991), subseq uently resulting in a decrease in PTI-lrP mRNA
ex pression. However, this cennoeexplain the observed incrcase in PTHrP maNA expression
in respo nse to 17~-estradio l trea tme nt in CaSki cells. 1 7~-Estradio l has been shown 10
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increase EGF recepcor (EGFR) Ievetsjn various tissucs (Mullu VRand StarICe'l OM, 1985 :
Gardner RM ~t ol, 1989). Forexample,y,-hcn l1Jkstradiol wasadministered to fema1era ts .
it produced increases in EO FR jevets which were sugg ested 00 be media led by a
tTanscrip tional mechanism( M ukku VR andStaneei O M. 1985). InHEC-16 cells.,the effec t
of 1713-estrad iol on EGFR mRNA levels has been examined (Gogai L. 1998). An increase in
EO FR mRNA would sugges t that estrogen may act in a similar fashion 10 EOF to increase
PTHr P mRNA express ion, In HEC-16 cdls, 17p..estradi o l was indeed found to increase
EOF R mRNA levels (Gogal L. 1998). These resul ts support the possi bility tha t 17p...
estradiol-st imulated changes in EG FR number could stimulate the synlhesis of PTHrP. An
ERE has noCbeen found in the promoter region of the PTI-lrP gene . Th.is furthersuppo rts
the poss ibili ty that 11p -estrad iol may act via EOFR al a transcriptional level to modulat e
PTHrP mRNA expression in HEC-16 . as well as in CaSki ce lls.
Progesterone has not previously been shown to produce an increase in PTHrP expression in
olhertissues. For example. in both rat uterus ill vivo (Thiede M A et ai, 1991) and in rat
Leyd ig cell tumour H-500 ce lls (Liu B et al, 1993), thcTewas e decreese in PTHrP mR..'iA
ex press ion after lJ'ealtnent with ptogesterone. In cu ltured human endometrial cells,
progestins also produced a decrease in PTHrP prod ucti on (Case y ML et al ; 1993) .
However, in HEC-16 cells (Rahi mrula M and Kaiser SM , submined) , progestero ne was
10.
observed to increasePTH rP mRNA levels in both a dose- and time-dependent manncf.
Although a change was not observed in dose-response stud ies , a significant increase in
PTHrP mRNA wassecn in ti me course studies in response to proges terone. An increase in
EGFR may explain the cbange in PTIlrP mRNA in respo nse to progeste rone . The effect of
proges terone on EGFR has been studied both in vitro and iff vivo with variable results .
Progesterone did poducean increasein EGFR numbers in bwnan breasa cancer cejls (Lange
CA er al, 1998). In the:hwnan uterus , progesterone modified endomc1ria.lEGFR with a
decrease in endometrial EGFR numbers in the secretory phase o f the menstrual cycle . in
response to progesterone lev els (Jasonni VM et ai, 199 1). In the established and mal ignan t
cells we have studied, potential chang es in EGFR mRNA in respo nse to progesterone. have
not been examined. Evidenceofa PRE has aol been found to date in the promot er region of
the PTHrP gene. This sugge sts tha I progesterone. like estrogen. may ecrease EG FR at a
transcri ptional level to prod uce an increase in PTHr P mRNA expression in thesecell s. It is
also plausible that a comp letely separate mechanism ex ists whereby the expression of
PTHrP mRNA in CaSki cells is altered .
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Rec ent stud ies have reported thaI malignant trans formation of sex-ste roid-dependenttiss ue s
is o ften associ ated with a loss of express ion of sex steroid ho rmo ne receptors (Kanai M n
al , 199 7). Malignant transformation a ( tbe squamous ep itheliwn of the uterine cervix may
sim ilar ly result in aberTant expre ssion of steroid bonnone receptors . While the presence of
the estrogen rece ptor has been reported in all samples o f nonnaJ cervical tissue (Sou n er WP
and Leake RA, 1987) . several investigators have measured ER and PR leve ls in cervical
cancer. The expression o f PR and ER in cervical ti ssues has been contro versial in tha t a
vari able proportion of PR and ER exists in different sampl es ofcervical tiss ue (Ciocca DR
et ai , 1989; Konis hi I et al , 199 1; Robertson DI et al. 199 3). For example. using
immunohistochemical {Vargas-Roig LM et al, 1993) and ligand-binding assay s (Hahnel R et
al 1979 ). very low or unde tectable levels of ER and PR we re reponed in one stud y of
cervi cal ceocer . Others ha ve repo ned somewhat higher leve ls (Foo:I LC et al, 1983; Gao YL
et ai , 1983). The differences amon g studies may be due to di fferences in methods o f tiss ue
collection. steragecond itions.assay techniq ues and perha ps in patient pop ula tions . We have
not tes ted CaSe cells oursclves to ascertain if 1hey do indeed possess PR and/ or ER. In one
study usi ng CaSIri cells, three assa ys were negative for both receptors (Gre nman S el ai.
198 8) . However. it is nol stated wh ich methods or which cond itions were used to test for
the pre sence or absence of thesereceptors. Funh er inv estigati on using imm uno blot anal ys is
has confirmed that CaSki cells do possess the high-affinity 56 lOa estrog en rec eptor
(Macinga D et ai, 1995) . G iven that estrogen prod uced increase s tn PTHrP mRNA . and th a t
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these response s may be mediatedvia ER, it is proba ble that ER numbers were suffic ient to
bring about the chang es in responseto the 17P-estradiol. In one study using ectocervi cal
cells, estrogen receptor leve ls were greatly diminishedin cell s posi tive for the:HP V genome
(Macinga 0 er aJ, 1995) . thus suggesting a selective advantage that may exist fo r malignan t
cervical ce lls with nonfunctional ER pathways . Alchough a separa te mechani sm may exist
for progesterone's action on CaSIcicells, isalso poss ible that PRs were present and the ir
numbers may have been sufficient. as confirmed in the pre sent studies. to brin g abou t a
change in response to pro gesterone.
17~-Estradio l also prod uced an increase in iPTHrP secretio n. iPTHrP prod uction increased
ncar ly 2-fold compared to basal (time zero). This increase in PTHrP secretion was likely due
10 tbe upregulatioD of PTHr P mAN A levels. However . there was no signi fican t increase in
iPTH rP sec retio n afte r progesterone treatment in both dose - and time -depcndcnt
experiments. The question arises as to how progesterone could prod uce an increase in
pmrP mRNA buc fail to elicit a signi rteanl increasc in iPTI-lrP secretion. The po ssi bi lity
ex ists that a PRE co nse nsus sequence may DOl exist, o r one:with a similar functi on. or that
progesterone may act thro ugh a different response clement all logether within the gene.
Neve rtheless, given that an increase in P"lThPmRNA was indeed observed in respo nse to
progesterone, the question remains as to why iPTH rP sec retion was not affec ted . It is
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known thai the leve l of iPTHr P secretion was not less than the detection limil ofthc RJA.
A possible explana tion for the lac k of response is that the increase in PTHrP produced in
response to progesterone is rapidl)' dcgnded. either inlraCe llular l)' or cXlJ'aCellularl )' . to a
norummuooreective prod uct. This is unlikely given that other factors simi larly increased the
secretion of iPTHrP which co uld be detected by the RIA . It may also be tha t intracellular
PTHrP is being produced within the CaSki ce lls but is simply not being secreted. It is eve n
possible that alternate promot en ex ist and are uti lized in the presence o f progesterone and
not in the presence of any other hormones/growth factors used in experim enta tion. II
remains WlClear as to w hy~ was a lack ofiPTHrP sec retion. There ma y be other levels
of co ntrol including post-transcriptional regulation or post- transla tional processing that
pre vents the secretion o f iPTH rP. Furthe r investigation woul d be nece ssary to determine
the reason for this findi ng.
These data suggest that. in cervical squamous c.arcinomas. the physiological ac tio ns o fThese
da ta suggest tha t. in cervical squamouscarcinomas.thc ph)'siologicalac tions ofesuogcnmay
be mediated, at least in part, by m trP. Further stud ies 10 explore changes in PTHrP
mRN A expressi on and protein levels in cultures of the cenicaI squamous CMCioomacel ls,
c aSki, wou ld be hel pful 10 better understand the mechanism whereby 17lJ<stra di ol and
prog esterone produce their effects .
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..... CASKl VERSUS HEC·16
Like HEC -16 cell s. both EOF, progesterone and 17Jks,tradiol increased PTI-lrP mRNA in
CaS ki cclIs whereas I,2S-dihydroxyvi tarninD) dCCl'CaSCd iu expression. Dcxamethasonca.so
dec reased PTHrP mRNA cxpression in the Ca Ski cells but at 24 hours no response was
apparent in the HEC· 16 cells. Dexame thaso ne did decrease PTIfrP mRNA expression in
HEC· 16 ce lls. bur nol until48 bours (Rahimtula M and Kaise r SM. submined ). Thus.. il is
evident tha t CaSkiceUshavea pattern o f responscof PTHrP mRNA similar to that of HEC-
16 ce lls .
There we re differences between CaS ki and HEC-1 6 cells however, in the chan ges in PTHrP
mRN A in response to stimulation wi th the vario us factors . For exam ple. EGF produced
about a l.5 -fold gtea lcr increase in PTHrP mRNA in CaSki cells than in HEC· 16 ce lls,
whe reas progesterone ueatment caused a25-fold grenee increase in PTI-trP mRNA in HEC·
16 ce lls than in CaSki cells. PTHr P has previously been noted to res pond d ifferently in
di ffere nt cells . For example. calcium caused an increasein PTH rP expression in cu ltured
Leydig cells (Rizzoli R ~I ai, 1989) howev er, it decreased its expression in a rat parath yroid
ce ll lin e (Zajac JD el ai, 1989). It is also known that PTHrP respo nds differently under
different cu lture co nditions .For example. Henderso nj et 01(199 1)dern onstratedtha r vary ing
the cal c ium concentration in the HPK IA cell line caused signi fican t difference s in PTHrP
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mRNA expression. CaSkicellswcre maintaincdin DMEM plus 10-10FCSandHEC-16 cells
were maintained in Keratinocyte Gm wth Medium (KG M) . Cons tituc ntsof lhe two media
diffe r and this may explain the difference in PTIlrP mRNA express ion between me two cell
lines .
Patte rns of iPTIlrP s«retion were similar in CaSki cells and in HEC-16 cells. That is. EGF
and 17ll-estradiol both increased iPTHrP secreti on, whe reas dexamethasone and 1.2:5-
dihydroxyvitamin DJ bo th decreased secretion at 24 hour s. Progestero ne stim ulation
produ ced a significant increase in iPTHrP secret ion in HEC-16 ce lls at 24 hours.
Proge stero ne did not significan tly change iPTH rP secre tion in CaSki cells. Furth er
investi gation would be necessary to dctcmrlne the reaso n for this difference in sec retion
between the two ceil type s. Noneth eless, these results demonstrated that the malignant
CaSki cells secreted sigruflcaml y less iPTHr P than did esta blished HEC-16cell s. There was
an obvio us dysregulatio n o f PTHr P in the malignant ce ll line .
My data suggcsts th.at increasedPTHrP geneexprnsion contributcsto an tecreasein iPTHr P
secreti on. However , compared to immortalized cells, the lev el of iPTH rP secretion in CaSki
cells has dramatic ally decreased. Reaso ns for the decrease in iPTHr P an: not known but.
co ns idering the possibi lity o f PTHrP' s involvemen t in cell growth and differentiation. the
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decrease inPTItrP secretion may provide a selective advantage to these malignant cells with
respect to their growth and differen tiation. As HH M is characterized by an increase: in
circulating levels of iPTI-lr P within the body.lh.is eeceease in iPTI-lrP secretion by malignant
ce lls may explain why gynecologic malignancies are not commonly associated with HHM .
...s FlJI11RE D1REcnONS
It wo uld be info rma ave to investigatethc effects ofan estro genar aagonist, suc h as tam oxifen
or raloxi phene, on prnrP exp ression and secretion. It is anticipated that tam oxifen wou ld
decrease PTHrP prod uct ion. We anti cipat e the se results as 17j3,-estrad iol increased PTIf rP
mRNA expressio n and sec retio n in CaSlcicells and tamoxifcn is an anti-estro gen. Dose- and
tim e-dependent experiments co uld be performed 10 examine the effect of tamo xifen on
PTI-lrP expres sion in cervical squamous carcinoma cells . It is poss ible that tamoxifen co uld
reverse or antagonize the effec ts o f estrog en in these cell s and thus pro vide a new approach
to the mana gement of HHM Of" more inlcrestin gly. the gro wth of the tumour cells .
It wo uld also be infonnative to treat CaSki cells with cycloheximide and to perform nuc lear
run off assa ys afte r treating the cell s with various hormone s and factors ( in partic ular. EG F
and 17j3,-estradiol as these two factors produced the largest increases in PTHr P express ion
in CaSki cells). Thi s wou ld determine: whether the inc rease in mRNA express ion is due to
lIS
an increase in mRNA stability. an Increasein transcription or beth,
Ano ther poss ible srudy would be toassess the effect of PrnrP on the gro wth rate ofCaSki
cells. NeutraJizing antibod y would be added to the culture medium during time course:
experiments and ceu num bers would be ass essed at timed intervals. These resul ts wou ld be
compared to cell numbe rs obtained in curre nt experi ments performed witho ut the additi on
of a neutral izing antibody. Th is relatively simp le experiment wo uld allow us to conc lude
whether or not PrnrP has an effect on the growth of these cells.
Immunocytochemistry co uld be perlormed to confinn the presence Of absence o f PTH rP
protc in in these ectocervicalsquamo us carc inomacells. The patte rn of staining (for exam ple.
cyto plas mic and/or nulceolar staining) would yield useful information with respe ct to
funct ions of PTH rP, other than those classically mediated via interactio n with its G-protein
cou pled receptor .
4.6 CO SCLUS IO NS
The cervical sq uamous carcinoma ceUsuscd intbese stud ies had been infected with HPV·16.
the virus most co mmo nly assoc iated with cervical carcinoma.. Treatment o f these cells with
various honn ones and factors affected the expressi on of PTHrP mRN A and iPTHr P
secret ion . No t only did the previously studied regulators (EG F. dexam ethaso ne and 1,25-
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dihydroxyvitamin 0 ]) have a significan t influence on PTHrP express ion and secreti on. but
the tissue-spec ific regula tors. estrogen and progesterone. also prod uced the similar e ffect.
Whereas cervical carcinomas are not conventionall y comidem:t to be steroi d-hormone
responsive . these changes in response to estrogen and progesterone suggest a po ten tial for
modulation . Thi s co uld be assessed in our model using tamoxi fen., othe r an ti -estro gens or
anti-progesrins . Altho ugh these cervical carcinoma cdls did not have a signi fican t response
in iPTHr P secretion in respon se 10 progestero ne. the pos sibility remai ns that modul ation of
PTHrP secretion migh t occur in other, proge sterone receptor-positive ce lls. The speci fic
effects of PTHrP would have 10 be furth er analyzed through furthe r expe riemntation to
determine PTH rP"s specific effects of cervical cancer . Although furthe r investig ation is
necessary , it is possib le that PTHrP may act as an intrac rine growth regulator with in these
cevic al ceus.
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APPENDlX A
Biocb~m ical Uails r~I.1 C. lf Serum
Compoa~at raDC~
Total protein o'dL 6.9 (6. 1- 7.5 )
PH units 7.6 (7 .3 - 8.1)
Osmolarity """"",,g 292 (273 - 310)
Glucose mg'dL 105 (90 - 118)
Hemoglobin mo'dL 15.2 (10 .2 - 23 .2)
Bilirubin mo'dL 0.2 (0. 1 - 0 .4 )
Uric Aci d mo'dL 0.9 (0 .8 _ 1.0)
Ure a Nitro gen mo'dL 10.0 (6 · 13)
Creatinine mg'dL 1.1 (0 .7 - 1.6)
Sodi um m<qIL 137 ( 134 - 142)
Potasium m<qIL 5.5 (4.9 - 6.0)
Calciwn( total) "O'dL 9.9 (9 .7 - 10.0 )
Chloride ""'I'dL 106.7 (99 -112)
Phosphorous(inorganic) mg'dL 76 (6 .8 -8.4)
Iro n (t otal)
. o'dL 74 (53 - 93)
Albumin o'dL 3.6 (3 .4 -3 .8)
Globulin (total) o'dL 3.3 (2.6 . 3.7)
Alkaline Phosphatase U/L 188 (125 ·29 5)
GG·Transpcplidase U/L 53.3 (2 1 -79)
SGOT U/L 83.3 (64 .94)
Lactate dehydrogenase U/L 1067 (975 - 1220)
Chole sterol mg'dL 78.3 (95 - 121 )
Low Density Lipoprotein mg'dL 56.7 (5 1 - 72 )
High Density Lipoprotein mg'dL 36.7 (4 1 - 63 )
Triglycerides mg'dL 16.3 (15 . '7)
Growth Honnone
"""""
26 ( 14 - 35)
Insulin oillJlmL 5.' (4.2 · 6 .8)
Estradiol
"""""
32.9 (22.2· 39.2)
Progesterone
"""""
1.65 (0. 88 - 2.20 )
Te sto stero ne
"""""
1.05 (0 .79 - 1.19)
T4 (Thyroxine)
.wmL 9.2 (1 .8 . 10.0)
T3
"""""
1.9 (1 .5 -2.5 )
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